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OBJECTIVES:  
           To identify the types of patients who talk with their physicians as a result of Direct-
to-Consumer (DTC) advertising.  
 
METHODS:  
            Data were taken from a national survey, “Public Health Impact of Direct-to-
Consumer Advertising of Prescription Drugs, July 2001- January 2002”, conducted by 
researchers from Harvard Medical School. Participants (n = 3000) were interviewed by 
telephone. We constructed a conceptual framework consisting of outcomes (3 types of 
physician visits), intervention (DTC experience) and five groups of explanatory factors 
(health beliefs, demographics, health status, socioeconomic status and market factors). 
Data were analyzed with three multivariate stepwise logistic regressions. The three 
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dependent variables were whether an advertisement for a prescription drug had ever 
prompted the patient to: 1) visit to discuss prescription drug, 2) visit to discuss new 
condition, and 3) visit to discuss treatment change.  
 
RESULTS:  
             Out of all independent variables, only six variables consistently showed significant 
effects on the three dependent variables after adjusting for other variables. They were: 1) 
taking medication on regular basis, 2) having anxiety, 3) having high advertisement 
attentiveness, 4) viewing media as the most important source prompting one to talk with 
physician, 5) believing that DTC advertisements increased awareness of new treatment, 
and 6) believing that DTC advertisements improved discussion with health professionals. 
The six variables were the strongest predictors for DTC-prompted physician visits. 
 
CONCLUSIONS:  
             Our nationally representative study found multiple factors were associated with 
different types of physician visits prompted by DTC advertisements. This information 
could be used to target those patients most likely to talk to their physicians as a result of 
DTC advertisements.  
9 
  
CHAPTER 1 
INTRODUCTION 
 
             In 2003, the pharmaceutical industry was estimated to spend over $3 billion on 
direct-to-consumer (DTC) advertising in the United States and spending on DTC 
advertisements quickly climbed between 1996 and 2003. (IMS, 2004; Rosenthal, 2002)  
Some research attributed the escalated DTC advertising expenditure to the relaxation of 
regulation from the Food and Drug Administration (FDA) in 1997. (Rosenthal, 2002; 
Kaiser, 2001; Joel, 2001;Weissman, 2003) However, it was only part of the story. Many 
driving forces were behind the increases in DTC advertising. Over the last two decades, 
great changes occurred in the U.S. health care system.  These changes contributed 
substantially to the growth of DTC advertising. 
 
Driving forces behind DTC advertising 
             In addition to FDA regulation relaxation, several forces facilitated the growth of 
DTC advertising in the healthcare market.  
 
More flexible drug formularies 
             According to Academy of Managed Care Pharmacy (AMCP), a drug formulary is 
“a continually revised list of prescription medications which represent the current clinical 
judgment of providers in hospitals, health plans, and physician groups under contract with 
health plans.”  (AMCP, 2002) It is an essential tool utilized by managed care to control 
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drug costs and ensure appropriate drug therapy. With closed or single-tier formularies, the 
plans only cover certain drugs. If plan enrollees want to use prescription drugs not on 
formularies, they are required to pay out-of-pocket for the entire cost of those medications. 
As limited or tightly controlled drug formularies have been responsible for considerable 
dissatisfaction among patients and physicians, more health plans are shifting their 
formularies from single-tier or 2-tier to 3-tier formularies. (Briesacher, 2004) According to 
the Annual Employer Health Benefits Survey by Kaiser, the use of 3-tier drug plans has 
nearly doubled in recent years, from 29% of covered workers in 2000 to 57% in 2002. It 
was reported that currently no more than half of health maintenance organizations (HMOs) 
and only 10% of employer-sponsored health plans use closed formularies. (Carroll, 2002)  
Many plans applied 3-tier formularies to loosen their restrictions and improve drug 
coverage by requiring patients to pay more out of pocket. In contrast to single-tier 
formularies which normally only cover certain drugs, 3-tier formulary systems cover a 
broader range of drugs, but may require patients to pay higher copays.  Three tier 
formularies set the lowest co-payment for generic drugs, a higher co-payment for 
formulary or preferred brand name drugs, and the highest co-payment for non-formulary 
brand name drugs. (Briesacher, 2004) Consumers are informed of differential co-payments 
and given the option to pay more to receive drugs in higher tiers. Therefore, as formularies 
became less restrictive and managed care shifted more drug costs to patients, patients have 
become more engaged and conscious of physicians’ prescribing decisions and have started 
to seek alternative information sources to support their medical decisions. (Hunt, 1998) 
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Getting health information from DTC advertisements is potentially one of the choices. 
(FDA, 2001) 
 
Restrictions in promotion to physicians  
             Today, managed care organizations (MCOs) have brought in new policies for drug 
selection. These policies require that new products demonstrate either cost advantages or 
therapeutic advances over existing therapies. They limited physicians’ ability to prescribe 
expensive prescription drugs through a number of mechanisms, including higher co-pays, 
generic substitution, and drug utilization review. (Hunt, 1998) These policies have placed 
pressure on drug manufacturers and made it more difficult for them to promote their 
products to physicians, especially those with little therapeutic advantage or those that treat 
“life-style” conditions, such as baldness or obesity. (Hunt, 1998)  DTC advertising 
provides a way to stimulate demand for these products, especially when they possess 
milder side effects or easier dosing forms. Therefore, as formularies become more flexible 
in allowing patients to choose their preferred drugs, patients can help the industry break 
physician’s static prescribing patterns by asking for new drugs directly.  
 
Changes in the FDA regulation 
             Since 1962, the FDA has regulated the advertising of prescription drug products 
under the Federal Food, Drug, and Cosmetic Act and related regulations. In Section 502(n) 
of the Act, there were two key provisions on labeling and prescription drug advertising. 
One was “brief summary” and the other one was "fair balance". “Brief summary” meant 
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labeling must include "such information in brief summary relating to side effects, 
contraindications, and effectiveness.” (FDA, 1999)  In fact, the summary was not “brief”. 
It typically required several pages. The manufacturers therefore found it extremely difficult 
to meet the brief summary requirement in a short television (TV) or radio advertisement. 
At the same time, the body of the advertisement must give "fair balance" to the benefit and 
risk information. That is, claims of drug benefits, such as safety and effectiveness, must be 
balanced with relevant disclosures of risks and limitations of efficacy. An advertisement 
was deemed to violation of section 502(n) if it was false, misleading or lacked “fair 
balance”. (FDA, 1999) 
             In August 1997, the FDA reviewed its policies on broadcast advertisement and 
issued “draft guidance” to manufacturers. (Rosenthal, 2002) In this new guidance,  “brief 
summary” can be replaced by "adequate provision” which is permitted by the FDA for 
“dissemination of the approved or permitted package labeling in connection with the 
broadcast presentation.” ((21 CFR 202.1(e)(1)) In details, the radio or TV advertisements 
may meet the adequate provision requirement through an approach that will allow most of 
a potentially diverse audience to have reasonably convenient access to the advertised 
product's approved labeling. The approach must include the following components: a toll 
free phone number, a print reference to DTC advertising, an Internet address, and a 
statement that directs consumers to physicians or pharmacists for further information. 
(FDA, 1999)  However, advertisements broadcast through media such as television, radio, 
or telephone communications systems must disclose the product's major risks in either the 
audio or audio and visual parts of the presentation. (FDA, 1999)  Without the need to 
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include detailed risk information that accompanies magazine and other print 
advertisements, TV and radio quickly become popular promotional tools in pharmaceutical 
marketing.  
 
More drugs suitable for DTC advertising 
           The U.S. health system has changed from primarily treating acute conditions to 
treating more conditions that are chronic. (Williams et al., 1999) Many chronic diseases are 
associated with age and are not curable. Drugs treating these diseases usually are 
repeatedly used over a lifetime. Some chronic conditions such as hair loss, erectile 
dysfunction (ER), and obesity lacked effective drug treatments before the late 1990s. Some 
physicians also called them “lifestyle” diseases or "non-diseases". (Joel, 2001; Smith, 
2002) Since the late 1990s, the pharmaceutical industry has introduced a number of new 
drugs treating these diseases. Viagra for ER, Propecia for baldness, and Meridia for 
weight-loss were good examples. These “lifestyle” drugs became very popular in the 
market as consumers became more concerned with better quality of life in their healthcare. 
Furthermore, other new prescription drugs emerged in the market that possessed milder 
side effects or easier dosing forms than the comparable older drugs (NIHCM, 2002). 
However, these products had neither cost advantages nor therapeutic advances over 
existing therapies. These new drugs and the ‘life-style” drugs usually are not covered by 
managed care plans (Hunt, 1998). DTC advertising provides a way to stimulate demand for 
these products  
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Intensified demand for health care information  
          Since the 1990s, many patients have expressed desire and interest in active 
participation in their own healthcare. (Knapp, 2000) One of the important reasons was the 
decline of trust in physicians. (Hunt, 1998) Consumers gradually became aware of 
managed care mechanisms, such as restricted formularies and financial risk sharing by 
physicians, and this awareness has tended to undermine their faith in physicians as agents 
acting in their best interests. It led patients to seek outside information on drug therapeutic 
alternatives, such as DTC advertisement. (Hunt, 1998)  
 
 
The benefits and risks of DTC advertising 
          As a drug has benefits and risks, DTC advertising not only has its benefits, but also 
raises concerns about misleading information. This results from the ethical dilemma of 
marketers who sponsor DTC advertising: as health product providers, pharmaceutical 
manufacturers are responsible for the optimal use of medications, however, as business 
units, making maximum profit and surviving in the market is their goal. This conflicts of 
interest may lead to biased information in DTC advertisements. (Mello et al., 2003; 
Mintzes et al., 2002) At the same time, if a drug has little therapeutic advantage over other 
products in the same class of drugs, and has an inflated price as a result of heavy DTC 
advertisements, the practice would lead to waste in healthcare resources. In some extreme 
cases, when the drug may potentially cause long-term risks to patients, the impact would 
be even worse. For example, in December 2004, Merck had to announce a voluntary 
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withdrawal of vioxx from the market because the FDA reported that patients taking Vioxx 
chronically face twice the risk of severe cardiovascular events compared to patients 
receiving a placebo. (FDA, 2004) Ironically, this drug has been one of the most advertised 
brands through DTC advertising since its successful launch in 1999. In 2000 alone, Merck 
spent over $160 million on media advertising for Vioxx. (Kaiser, 2001)  
          Therefore, with deeply planted conflicts of interest, DTC advertising and its impact 
on public health is like a double-edged sword with negative side and positive side. Deeper 
discussion about the two sides is necessary for a better understanding of influence of DTC 
advertising on patients’ health behaviors. 
 
Benefits of DTC advertising 
Increase in awareness of under-diagnosed and untreated diseases 
           The FDA and the government agencies are concerned with untreated and under-
treated disease among the population. The National Institute of Health (NIH) guidelines 
stated that for every 100 patients who should be treated with drug therapy for high 
cholesterol, currently only 25 patients are under treatment. (NIH, 2001) The Centers for 
Disease Control and Prevention (CDC) also reported that 25% of all working-age people 
with high blood pressure did not even know they have it. (CDC, 2001)  As a result of these 
concerns, the FDA (FDA, 2002) expected DTC advertising to help educate patients to 
some extent and make them recognize the symptoms and harms of diseases.  
           Surveys have shown DTC advertising does alert consumers to the existence of 
diseases and leads patients to search for more information. (FDA, 1999 & 2002; NCL, 
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1998; Prevention, 1998, 1999 & 2001; Kaiser, 2001) Among surveyed consumers, 67% 
agreed that advertisements increased their knowledge about disease. (NCL, 1998) 
However, to what extent patients gained knowledge from advertisements was still in 
question. Kaiser found that after seeing an advertisement, 70% of survey consumers knew 
little or nothing more about the health condition for which the drug was indicated. (Kaiser, 
2001) Some patients, therefore, sought more sources of drug information after seeing drug 
advertisements. FDA surveys revealed that 43% to 53% of patients searched for further 
information through such sources as the Internet, newspapers, and friends. (FDA, 1999 & 
2002) 
 
Increase in awareness of drug treatment 
            A number of surveys (FDA, 1999, 2002; NCL, 1998; Prevention, 1998, 1999 & 
2001; Kaiser, 2001) indicated that DTC advertising enhances treatment awareness. This is 
understandable since the basic function of DTC advertising is to offer education on 
prescription drugs. With DTC advertisements, patients have more chances to know 
available treatments for their diseases and to be prompted to discuss the new treatments 
with their physicians. It potentially increases patients’ accessibility to therapeutic 
alternatives. Roth (Roth, 1996) classified DTC advertisements’ contribution to treatment 
awareness into five categories. The first one was new therapies used to treat conditions that 
were formerly untreatable or poorly treated, such as erectile dysfunction or Alzheimer’s 
disease. The second was drugs for conditions that tend to be under-diagnosed and under-
treated, even though drug therapies were available, for example, hypertension or high-
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cholesterol. The third category was drugs that lower risks or have milder side effects, and 
so expand the number of patients who can tolerate drug treatment. The fourth was brand 
products that have cheaper, generic or over-the-counter (OTC) equivalents. The last 
category is products with little benefit but that are safe and easy for physicians to prescribe. 
According to this study, DTC advertisements for the first three categories offer patients 
better therapeutic options. Advertisements for the last two lead to higher drug costs. 
 
Enhance patients’ involvement in their own healthcare 
            Major national surveys also indicate that about one fourth of patients were 
prompted by DTC advertisements to discuss with their physicians advertised treatments 
that were related to their health. (FDA, 1999, 2002; Prevention, 1998, 1999 & 2001; NCL, 
2002; Kaiser, 2001) Most patients (74% to 76%) agreed that DTC advertisements allowed 
them to be more involved in their health care. (Prevention, 1998 & 1999) The involvement 
includes searching for related health information; increased physician visits, better 
discussion with physician about health conditions or new treatments, and improved 
compliance with the advertised medication. Physicians felt comfortable about patients 
playing an active role in their healthcare, and they would like to see this involvement. 
(FDA, 2002)  Patients’ compliance to medications also showed some improvement as a 
result of DTC advertising. In the Prevention study, approximately one-fourth of the 
respondents reported that DTC advertisements reminded them to refill their prescriptions 
(Prevention, 2001). A FDA study reported a lower rate, 10%. (FDA, 1999) A case-control 
study by Pfizer also indicated that patients who took the advertised drugs that they 
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requested from physicians are significantly more likely to refill their prescriptions than 
those who did not initiate a request. (Pfizer, 2001) 
 
Concerns about DTC advertising 
Misleading or deceptive information 
           According to 21 CFR.202.1 (FDA), misleading or deceptive information in DTC 
advertising includes 1) misrepresenting or falsely reporting data, 2) declaring superiority 
without scientific data to support the claim, 3) suggesting the drug is better than another 
before it is proven, and 4) representing "off-label" use (new indications that are not 
approved by the FDA). (FDA, 2004)  
            However, pharmaceutical manufacturers continue to deliver misleading 
information to consumers in DTC advertisements. Between August 1997 and August 2002, 
the FDA issued 88 regulatory letters and four warning letters for DTC advertisements that 
violated its regulations. Among the letters, there were 14 letters to GlaxoSmithKline, six 
letters to Schering Corporation, and five letters to Merck & Co. Inc., all about their 
misleading advertisements. (GAO, 2002)  It was reported that half of the regulatory letters 
issued by the FDA in 2001 had cited advertisements that made misleading claims about a 
drug’s efficacy. For example, in August 2001, the FDA sent a warning letter to the 
distributors of Luxiq cream, a dermatological product, for falsely reported data. Its 
advertisement claimed that the product was “highly effective for three out of four patients”, 
even though the clinical study cited in the labeling had found that the cream improved 
various symptoms for 41% to 67% of patients, or no more than two in three. (GAO, 2002) 
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Unbalanced information on benefit and risk 
            Researchers have indicated that many advertisements tend to allot more space to 
the positive features or drug benefits, while minimizing information about risk and adverse 
effects (Mello, 2003; Mintzes et al., 2002). The FDA’s Division of Drug Marketing, 
Advertising and Communication (DDMAC) raised complaints about the lack of risk 
information in DTC advertisements (Smith, 1998). These complaints included: 1) lack of 
reference to risks, adverse effects, and side effects; 2) not presenting risk information in a 
prominent and readable manner; 3) using confusing language and technical terms that are 
often misunderstood by the general public; 4) showing claims of safety not substantiated 
by well-controlled studies; and 5) not providing balance between risk and efficacy, e.g. 
small type for the risks and large type for efficacy. However, unbalanced information may 
be inherent in advertisements, because the purpose of advertisements is to promote 
products rather than to deter patients from using them.  
           
Increase unnecessary physician visits and inappropriate drug prescribing 
           Some experts pointed out that brand-specific requests by patients may lead to 
inappropriate drug prescribing because patients may not be able to correctly self-diagnosis 
their disorders or symptoms. (Lexchin, 2002)  In the opinions of researchers, patients 
usually lack sufficient knowledge to self-diagnose. Therefore, it is unlikely that patients’ 
brand-specific requests are necessary or correct. Researchers also found that physicians are 
more likely to become irritated from patient queries originating from DTC advertisements 
  
20
rather than other sources of information. (Zachry, et al, 2003) Surveys of physicians and 
patients in primary care settings also showed a strong association between a physician’s 
decision to prescribe and their perceptions of patient desire for a prescription even when 
they know the drugs are not indicated. (Himmel et al., 1997; Schwartz, et al, 1989) 
Therefore, if patients pressure physicians into prescribing the advertised drugs, the practice 
may lead to inappropriate prescribing behavior. Interestingly, another study indicated that, 
despite concerns about DTC advertisements’ negative consequences, there were no 
differences in health effects between patients who took requested advertised drugs and 
those who took other prescription drugs. (Weissman, 2003) 
 
Increase in drug costs 
            Both the public and the pharmaceutical industry are highly concerned about costs.  
From the public side, most brand-name drugs promoted in DTC advertisements have 
higher prices than their therapeutic alternatives, especially their generic alternatives. If the 
brand-name drugs were new therapies used to treat formerly untreatable or under-treated 
conditions, or if they had lower risks or milder side effects, they would be better choices in 
clinical practice. In this case, the advertised drugs’ higher prices would be acceptable. The 
news drugs, regardless of the level of improvement, have cost industry billions of dollars 
in research and development (R&D). Their R&D costs need to be recovered. This may 
require spending even more money on promotion in hopes of gaining enough profit from 
the market to support further research investments. The costs will be shifted to consumers 
through inflated prices on drugs.  Driven by cost considerations, Managed Care 
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Organizations (MCOs) have implemented new policies to limit the use of drugs with no 
cost advantages or therapeutic advantages over existing therapies. This forced drug 
companies to spend more money on DTC advertisements to promote these products. 
(Hunt, 1998) As a result of heavy expenditures on marketing, it was reported that in 2000 
the average price of advertised new drugs was nearly twice the average price of existing 
drugs prescribed for the same indications. (Dana, 2003)  
 
 
Return-on-investment (ROI) studies on DTC advertising 
            After investing billions of dollars in promotional expenditures, the pharmaceutical 
industry has great concerns about the value and cost-effectiveness of DTC advertising. 
Neslin’s return on investment (ROI) research indicated that, compared with other 
marketing promotion tactics, such as detailing, drug sampling, and medical journal 
advertisements, DTC advertising was not cost-effective. Neslin used a total of 391 
marketed prescription drugs’ data provided by Scott-Levin and PERQ/HCL from 1995 to 
1999. In the study, ROI was defined as the increase in revenue for each dollar invested in 
DTC advertising. Neslin found that for each additional dollar spent on promotion, the ROI 
was $1.72 for detailing, $5.00 for journal advertising, $3.56 for physician meetings and 
events, but only $0.19 for DTC advertising. (Neslin, 2001)  
            Why was DTC advertising less effective? There are two potential answers. First, 
DTC advertisements are not targeted. While DTC advertisements can focus promotion to 
some extent, the percentage of the audience relevant for the content is still low. Second, the 
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period of study 1995-1999 was probably a period of learning about DTC advertising. 
Pharmaceutical companies were still investigating which types of advertisements were 
most effective.  In addition, the regulations allowing DTC advertisements on TV and radio 
were not implemented until 1997. 
           A follow-up study conducted by Wittink looked at additional data through the year 
2000. The outcome was still not favorable for DTC advertising. Compared with other 
marketing tactics, DTC advertising had the lowest ROIs in every brand revenue category. 
Many of the brands reported low or negative ROIs. The study also analyzed three 
therapeutic categories: arthritis, asthma, and hypertension. Results showed DTC 
advertising had the lowest ROIs (only $ 0.1) in each of the therapeutic classes as well. 
(Wittink, 2002) 
           Kaiser’s study in 2003 suggested that DTC advertising had a positive ROI for five 
therapeutic drug classes. (Kaiser, 2003) The five therapeutic classes were antidepressants, 
cholesterol lowering, proton pump inhibitors, nasal sprays, and antihistamines. It was 
reported that increases in DTC advertising were associated with significant growth in drug 
sales. For every 10% increase in DTC advertising, total drug sales increased on average by 
1%. Each additional dollar spent on DTC advertising in 2000 yielded $4.20 in additional 
pharmaceutical sales that year for the 5 therapeutic drug classes.  
           In 2004, three years after Neslin’s study, IMS researchers conducted a new ROI 
analysis. This study examined 49 brands between 1998 and 2003. DTC advertising’s carry-
over effect and lifetime value were considered in the new model. The carry-over effect was 
a delayed response to DTC advertising. The concept of lifetime value was that once a 
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patient filled a new prescription attributable to DTC advertising, all the patients’ refills 
should be counted into the ROI of DTC advertising. IMS researchers found that when 
averaged across the entire database, new prescriptions generated by DTC advertising only 
accounted for about 20% of total DTC advertising contribution. Therefore, in most cases, 
whether or not the carry-over effect and lifetime value were considered made the 
difference between positive and negative ROIs.  The IMS study also found that 90% of the 
brands showed positive ROIs, 70% had over ROIs of  over $1.5 ROI, and 35% had ROIs 
of over $2.5 . (IMS, 2004)  
            Though DTC advertising showed better ROIs in recent years, the studies conducted 
by Kaiser and IMS failed to compare DTC advertising’s ROI directly with other marketing 
tools. Hence, there was no evidence that DTC advertising is more effective than the other 
common forms of marketing promotion. The IMS study also indicated that brands with 
sales below $200 million resulted in low or negative ROIs, which was consistent with 
Neslin’s study ($0.59 ROIs for DTC advertising). At this sales level, detailing had a ROI 
of  $3.70 and journal advertising had an ROI of $4.47. In other sales levels, DTC 
advertising also showed lower ROIs. It showed that even when DTC advertising’s carry-
over effect and lifetime value were considered for study, DTC advertising was the least 
effective among promotional tactics. 
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Statement of Problem 
            Studies on ROI indicated that the outcomes of DTC advertising showed no 
advantages over alternative promotional tactics. One of the most important reasons may be 
that DTC advertisements were not efficiently targeted to consumers. (Neslin, 2001) From 
pharmaceutical marketing prospective, further studies should examine the characteristics of 
patients who were interested in the DTC advertisements, offering a basis to investigate the 
types of patients who should be targeted with DTC advertisements.  
             Thus, the purpose of this study was to identify the types of patients who will visit 
their physicians as a result of prescription drug advertisement. Two questions are 
addressed in this study:  
             The first question is whether patients with different individual characteristics (such 
as health status, gender, or race) are more likely to visit their physician as a result of seeing 
a DTC advertisement for prescription drugs (DTC-prompted visits). The second question is 
whether patients’ health beliefs about DTC advertising are associated with their DTC-
prompted visits. Individual characteristics in this study consist of four groups of factors, 
including personal health status and healthcare utilization, demographics, socioeconomics, 
and market factors. These factors will be explained in Chapter 3. In terms of the DTC-
prompted visits, there are three types of visit experience. The first one is the experience of 
talking with physicians about a prescription drug for themselves. The second type is the 
experience of talking with physician about a medical condition, illness or other health 
concern of their own that patients had not discussed with physicians before. The third one 
is the experience of talking with physicians about possible change in treatment for a 
  
25
medical condition or illness that patients already had. Once the factors that interact with 
DTC advertising to influence patients’ physician visiting behavior are determined, 
marketers can use the information to target consumer groups more efficiently. 
 
                
Hypotheses 
           According to the two questions to be answered in this study, six hypotheses were 
framed:  
 
         H1: There is a statistically significant relationship between patients’ individual 
characteristics and whether or not they will talk with their physician about a prescription 
drug after being prompted by a direct to consumer prescription drug advertisement.     
           
         H2:  There is a statistically significant relationship between patients’ personal health 
beliefs and whether or not they will talk with their physician about a prescription drug after 
being prompted by a direct-to-consumer prescription drug advertisement 
 
          H3: There is a statistically significant relationship between patients’ individual 
characteristics and whether or not they will talk with their physician about a new health 
concern after being prompted by a direct-to-consumer prescription drug advertisement 
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          H4:  There is a statistically significant relationship between patients’ personal health 
beliefs and whether or not they will talk with their physician about a new health concern 
after being prompted by a direct-to-consumer prescription drug advertisement 
 
           H5: There is a statistically significant relationship between patients’ individual 
characteristics and whether or not they will talk with their physician about change in 
treatment after being prompted by a direct-to-consumer prescription drug advertisement 
 
            H6: There is a statistically significant relationship between patients’ personal health 
beliefs and whether or not they will talk with their physician about change in treatment 
after being prompted by a direct-to-consumer prescription drug advertisement 
 
 
Implications in practice 
             Findings from this study will help pharmaceutical marketers evaluate the influence 
of DTC advertising on physician visits in different consumer groups. The major national 
surveys have told us DTC advertising did influence consumers to some extent. These 
surveys reported that 70% to 99% of consumers were aware of DTC advertisements. 18% 
to 31% of consumers discussed advertised drugs with their physicians; and 6% to 9% of 
consumers requested advertised drugs from their physicians. (FDA, 1999 & 2002; NCL, 
1998; Prevention, 1998, 1999 & 2001; Kaiser, 2001) However, DTC advertising's 
influence on physician visits among different patient groups, such as elderly patients, 
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African-Americans, patients without prescription drug coverage and patients with different 
health beliefs, were not examined in these national surveys. Several local studies covered 
some of these issues based on their interests on patients’ attitude, value, and actual request 
behaviors, but none of them has answered the questions with nationally generalizable 
results.  
            Our study used nationally representative data to examine patients’ action in 
response to DTC advertisements. Based on the findings, marketers could identify the 
patients most likely to visit physicians as a result of DTC advertising, therefore, they could 
target consumers more efficiently. The marketers can use the study outcomes to develop 
customized messages and interactive tactics. Rather than the traditional media advertising 
on TV or radio, which just delivers messages to the audience without targeting individual 
differences, these customized messages and new technologies can make it easier to 
stimulate demand according to the characteristics of each individual. For example, using 
some direct response technologies on the Internet, marketers can send customized letters 
and brochures to those most likely to switch to new treatments based on the answers that 
respondents give to questions about their experience with a disease state or personal 
beliefs. At the same time, emails could be sent to them to direct them to a web site with 
information most relevant to their needs, such as the disease and new treatment knowledge. 
This would be more effective than simply directing them to a home page where they have 
to search for what they want. Therefore, as a result of more effective targeting based on 
consumer differences, the industry could improve their return-on-investment ratio for DTC 
advertising over time. 
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CHPATER 2 
LITERATURE REVIEW  
 
            The overview of the DTC advertising ROI studies told us that DTC advertising was 
less effective than other marketing tools. One possible reason may be that DTC advertising 
has not targeted patients efficiently. (Neslin, 2001) To solve this problem, further studies 
need to examine those patients who are interested in the advertisements and identify those 
who are most likely respond to DTC advertisements. So far, only a limited number of 
studies have identified factors influencing patients’ attitude and behavior toward DTC 
advertising. 
 
Factors influencing patients’ attitudes toward DTC advertising 
            A study from University of Rochester has explored what kind of patients would 
value the information provided by prescription drug advertisements using a Scott-Levin 
data set. This study reported that consumers with children or chronic diseases value 
prescription drug advertising more highly, while older consumers, recently sick patients, 
and more educated consumers are more likely to value their physician’s opinions instead. 
(Gonul et al., 2000)  
            A study by Doucette et al. looked at the effects of age and medication knowledge 
on the public’s desire for additional drug information following DTC advertising exposure. 
(Doucette et al., 1998) This was a mail survey with a random sample of 150 respondents. 
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They found that older and less knowledgeable people were less likely to report a desire to 
seek additional information, such as talking to a physician, after exposure to a DTC 
advertisement. Among the information sources (i.e. physicians, pharmacists, a family 
member or friends), physicians were the most strongly preferred for information on drug 
benefit and risk. The knowledge levels in this study were reported by respondents only, 
and may have been inaccurate. 
           Based on the results of a survey conducted by Prevention magazine, Sumpradit 
explored consumers’ attitudes towards DTC advertising. (Sumpradit et al., 2002) The 
study indicated that consumers who have ever asked their physicians for advertised 
prescriptions tended to agree that DTC advertisements made prescription drugs appear 
harmless and helped them make their own decisions on prescriptions.  
 
 
Factors influencing consumers’ responses to DTC advertising  
           In 1999, the FDA carried out a survey on DTC advertising, as part of an evaluation 
of the impact of the 1997 draft guidance on broadcast advertising. (FDA, 1999) In order to 
improve the report’s accuracy, the study included 960 (90%) people who had seen their 
physician within the past three months and 121 (10%) people who had seen their physician 
more than 3 months previously. The FDA found a significant difference in response to 
advertising between the two groups.  Only 8% in the former group reported bringing up a 
new health condition because of advertising, versus 27% for the later group (p < 0.001). 
Each group had the same proportion of people covered by health insurance. Those who had 
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seen a physician recently reported greater awareness of DTC advertising and significantly 
poorer health status than those who had not. This survey confirmed the results of other 
major surveys indicating that most consumers report positive responses to DTC 
advertising. However, except for heath care utilization (defined as a physician visit), the 
study did not examine other factors relating to people’s responses to advertising. 
             Kaiser conducted a case controlled survey on DTC advertising in 2001. (Kaiser, 
2001) Researchers used a new, internet-based survey technology to show respondents 
(viewer group) a particular drug advertisement and then asked them questions related to 
the advertisement. They also included a “non-viewer” group of respondents who did not 
view an advertisement and asked them similar questions.  There were a total of 1,872 
viewers and 639 non-viewers. Those with the greatest health needs, the elderly, and those 
who reported that they are in fair or poor health were found to be more likely to report that 
they talked to their physician about advertised drugs, though not more likely to receive a 
prescription for the advertised drugs. For example, 39% of those aged 65 or older and 41% 
of those with fair or poor health reported the experience of talking with a physician about 
advertised drugs as a result of seeing a drug advertisement (compared to 30% of the 
sample overall). In response to specific advertisements showed to them, those who have a 
relevant medical condition were more likely to anticipate that they would talk to their 
physician about the medicine. Significance levels on the differences were not stated in the 
results. 
            Sumpradit also explored how consumers’ characteristics interacted with DTC 
advertising to influence patient behaviors, such as asking for advertised prescriptions. This 
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study used a subset of 1,102 consumers who responded to a 1998 national survey 
conducted by Prevention magazine The findings indicated that consumers with chronic 
conditions and positive attitudes toward DTC advertising were more likely to have the 
experience of talking with physicians about the advertised drugs. (Sumpradit et al., 2002)    
            Peyrot et al. examined the effects of demographic factors, media exposure, attitude 
and prescription drug knowledge on requests for advertised drugs. (Peyrot et al., 1998) 
They carried out a random digit dialed (RDD) survey of 440 residents in Baltimore. The 
study showed that the belief that drug advertising reduces prices, preference for generic 
drugs, media exposure and drug advertising awareness were positively associated with 
drug requests, but the belief that physicians should be the sole source of drug information 
was negatively associated with the probability of request. The authors described the effects 
of different media exposure (i.e. print media exposure, television exposure) on patients’ 
responses to drug advertising, but in the published article, they did not clearly explain the 
concept of media exposure. Measurements for media exposure were also not described in 
detail by the authors. Rather than measuring the amount of awareness, this study simply 
measured drug advertising awareness with “whether awareness exists”, that is, respondents 
were asked whether they were aware of drug advertising or not. It was also one of the 
limitations pointed out by authors that “more comprehensive and in-depth measures of 
drug advertising awareness” should be developed. (Peyrot et al., 1998)  Univariate 
analyses found that women were more likely to request an advertised drug than men; 
whites than non-nonwhites; and professionals and better educated than those with less 
education. However, when the model was adjusted for attitudes and media exposure, no 
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statistically significant differences were found for race, gender and education. No 
relationship was found between age and requests for advertised drugs. The research did not 
include information on insurance coverage and health care utilization. The time of the 
study was in 1990, well before the changes to FDA regulations on DTC advertising in 
1997.  Exposure to DTC advertising was therefore much lower than it would currently be. 
All survey respondents were residents of central Baltimore.  This limits the generalizability 
of the study. 
            In a survey of primary care physicians in Sacramento, California, and Vancouver, 
British Columbia, researchers analyzed the association between advertising exposure and 
patients’ requests for advertised drugs. (Mintzes et al., 2003) A total of 78 physicians 
(Sacramento n = 38, Vancouver n = 40) and 1431 adult patients (Sacramento n = 683, 
Vancouver n = 748) were selected for study. Physicians were requested to complete a 
questionnaire about a patient immediately following the patient visits. In this research, they 
measured advertising exposure as the number of listed drugs a person had seen advertised. 
Researchers found patients with higher exposure to DTC advertising, patients who had 
conditions that were potentially treatable by advertised drugs, and those with greater 
reliance on advertising requested more advertised drugs. They used models controlling 
self-reported health status, use of healthcare service, health information source, age, sex, 
household income, and drug insurance coverage. Information on the significance of these 
factors was not reported in the study. This research was limited in that only respondents 
from two cities were surveyed, and one of the cities was in Canada where the healthcare 
system is substantially different from the U.S. healthcare system. 
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Summary of literature 
             A review of the literature showed that several factors have an impact on patients’ 
attitudes towards DTC advertising. Specifically, patients with children, chronic disease 
conditions (Gonul et al., 2000), less knowledge (Doucette et al., 1998), or former 
experience of asking for advertised drugs have positive attitudes towards DTC advertising 
(Sumpradit et al., 2002). While older, recently sick patients, or more educated consumers 
preferred physicians’ opinions rather than drug advertisements as sources of drug 
information (Gonul et al., 2000). 
            Studies also indicated that some factors can influence patient’s behavior of asking 
for advertised drugs. Multiple factors were found positively associated with drug request 
prompted by DTC advertising: the belief that drug advertising reduced prices, preference 
for generics, media exposure (including DTC advertisements), drug advertising awareness, 
conditions potentially treatable by advertised drugs, and reliance on advertisements. 
(Peyrot et al., 1998; Mintzes et al., 2003). Patients who have seen their physicians recently 
(FDA, 1999), patients with the greatest health needs, elderly patients, those in fair or poor 
health (Kaiser, 2001), those with chronic conditions and positive attitudes toward DTC 
advertising (Sumpradit et al., 2002) were more likely to talk to their physicians about 
advertised drugs. 
            Although there were a number of national surveys, most of them were descriptive 
studies, and did not statistically analyze the relationship between patients’ response to 
DTC advertising and factors, such as demographics, health status, and exposure to 
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advertising, which may potentially influence patient’s behavior. Several studies conducted 
in more limited geographic areas examined the factors influencing patients’ attitudes or 
behaviors in response to DTC advertising. Because of limitations in sample size, location, 
or differences in nationality and healthcare system, few of them were generalizable to 
larger populations in America. Several studies have explored one type of physician visit, 
like talking to physician about advertised drug or request for advertised drugs directly, 
however, no single study has looked at the factors associated with different types of DTC-
prompted visits.  
            To enhance the understanding of DTC advertising’s influence on human health 
behavior, our research examined three types of DTC-prompted visits. The first type of visit 
was talking with physicians about a prescription drug for themselves. The second type was 
talking with physicians about a new medical condition. The third one was talking with 
physicians about switch to new treatment. Examining all three types of visits constructed a 
more complete picture of the effects of DTC advertising on patient’s interactions with their 
physicians. Furthermore, our study of factors that are associated with patient’s DTC-
prompted visits were based on nationally representative data. 
 
 
Conceptual framework 
           We developed a conceptual framework to explore how patients’ characteristics 
interact with DTC advertising to influence their physician visits. There is little theoretical 
guidance in the literature with respect to the structure of a model predicting patients’ DTC-
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prompted visits. However, the problem is not complex if we build the conceptual 
framework based on related theories and literature. The major constructs for our 
conceptual model were selected from two behavioral theories.  
 
The Theory of Reasoned Action  
             The Theory of Reasoned Action, as a general theory of human behavior, was 
introduced by Fishbein and was further developed and tested by Fishbein and Ajzen. 
(Fishbein et al., 1980) The theory attempts to explain the relationship among beliefs, 
attitudes, intentions and behavior. It is based on the assumption that human beings are 
usually quite rational and their behaviors are under volitional control. The theory views a 
person's intent to perform or to not perform a behavior as the intermediate determinant of 
the action.  Individuals will intend to perform a behavior when they are motivated by their 
attitude and subjective norms.  (Fishbein et al., 1980) That is, the behavior is more likely to 
be performed when they have positive attitude about the behavior and when they have 
positive normative belief, believing that important others (referents) think they should 
perform it. Instead of predicting patients’ intention to visit a physician as a result of DTC 
advertising, we used attitude and subjective norms to predict their behavior directly.  
            The Theory of Reasoned Action has been applied extensively in the health field to 
predict several health behaviors, such as smoking and exercise. (Kaplan et al., 1993) 
Recently, some mass media campaigns have successfully applied the theory in health 
promotion. (Randolph et al., 2004) These campaigns tried to focus marketing efforts on the 
factors and determinants that could potentially change consumer’s health behavior. For 
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instance, norms about alcohol consumption were successfully changed by a campaign to 
discourage binge drinking on college campuses. (Thombs et al., 2002) Oh and his 
colleagues also based their campaigns on the Theory of Reasoned Action to promote 
awareness of risks and screening for chlamydia, and proved to be successful. (Oh et al., 
2002)  
           In this study, we attempted to apply the Theory of Reasoned Action to patient’s 
DTC-prompted visits. When patients visit their physicians as a result of DTC advertisings, 
they are assumed to be under volitional control rather than being controlled by emotions. 
There are several potential reasons. First, patients are usually serious about their diseases 
and treatments. (Hunt, 1998)  Second, they value the recommendations from the sources 
(referents) that they usually receive healthcare information from, such as physicians, 
friends or TV advertisements; (Gonul et al., 2000) Third, when they initiate a discussion or 
request for advertised drugs during the visits, patients usually have knowledge about the 
disease and the new treatment. (FDA, 2002) A physician survey on DTC advertising has 
reported that when a patient asks about a drug, 88% of the time they had the condition that 
the drug treated, and 80% of physicians believed patients understood what condition the 
drug treats. (FDA, 2002) Therefore, the Theory of Reasoned Action can be applied to 
predict patient’s DTC-prompted visit. 
           Since the database used in this study lacked information on patients’ attitudes 
toward DTC advertising, subjective norm was the only variable adopted from the Theory 
of Reasoned Action. According to the theory, the potential referents or sources for 
healthcare information could be family and friends, pharmacists, physicians, television or 
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radio, and advertisements on TV and other media. We tested the relationship between 
patient’s behavior of being prompted to visit their physician and using advertising 
information as their subjective norms. For example, if DTC advertisement is a patient’s 
most important information resource for healthcare, then he or she should be more likely to 
talk to their physician about advertised drugs and request switches to new treatments.  
                                       
The Health Belief Model (HBM) 
            The Health Belief Model was developed in the 1950s to explain and predict 
individuals’ inaction or noncompliance to a certain interventional behavior. (Rosenstock, 
1988) It was the oldest and most widely used model specifically developed to explain 
health behavior. (Kaplan et al., 1993) The HBM proposes that behavior depends on how 
much a person values a particular goal and on his or her judgment that a particular action 
will achieve that goal. If the goal is to avoid a health problem, the person must feel 
vulnerable (perceived susceptibility) to a problem perceived to be potentially serious 
(perceived severity), and he or she must estimate that specific action will be beneficial in 
reducing the health threat (perceived benefit) and will not involve overcoming obstacles 
(perceived barriers). (Champion, 1984) Therefore, the model includes four principal 
components: perceived susceptibility, perceived severity, perceived barriers and perceived 
benefits. (Rosenstock, 1988) The theory has been applied to several areas of healthcare 
including preventive health behavior, adherence to medical regimens, sick-role behavior, 
and health promotion behavior. (Kaplan et al., 1993)  
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            From pharmaceutical marketing’s point of view, the goal of DTC advertising is to 
educate patients about the existence and severity of diseases, make them understand the 
benefit of advertised treatments, and finally prompt them to ask the physician to prescribe 
the advertised drugs. DTC advertising therefore could be looked on as an educational 
intervention for promoting patients to visit physicians.Limitations of the two theories 
 
Limitations on the Two Theories 
            The Theory of Reasoned Action and Health Belief Model both are psychosocial 
models. They account for only as much of the variance in health behaviors as can be 
explained by attitudes and beliefs that are obvious to and consciously evaluated by 
individuals. (Ogden, 2003) Other factors related to the individual, such as demographic 
variables, health status and health utilization factors, socioeconomic factors, and market 
factors, may play a role in influencing behavior, but they are not included in the two 
models.  It is the case that due to outside factors a person may not be able to perform a 
behavior despite a strong desire to do so. 
            To address this gap, our study also incorporated external factors, including personal 
health status, demographics, socioeconomics and market influence into the models to test 
their influence on the outcomes. The conceptual framework of the relationship between 
explanatory factors, intervention, and outcomes can be drawn as a flow chart. (See Figure 
2.) 
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CHAPTER 3 
METHODS 
 
            In this chapter, we will describe the source of data used in the study, define the 
variables in operational terms, and discuss statistical procedures that were employed for 
the analysis. In chapter 2, based on the Theory of Reasoned Action and the Health Belief 
Model, we constructed a conceptual framework consisting of outcomes, intervention and 
five groups of explanatory factors. The outcomes included talking to a physician about a 
prescription drug, talking to a physician about a new health condition, and talking to a 
physician about a possible change in treatment. The intervention was whether a patient had 
ever seen or heard an advertisement for a prescription drug in the past 12 months. The 
explanatory factors were personal beliefs, socioeconomics, demographics, health status, 
and market factors. Chapter 3 will operationalize the conceptual framework for predicting 
or explaining patients’ physician visit experiences as a result of DTC advertisements. 
 
 
Data source  
             This study used data from a national survey, “Public Health Impact of Direct-to-
Consumer Advertising of Prescription Drugs, July 2001- January 2002: [United States]” 
(Weissman, 2003). The data set was available from the website of Inter-university 
Consortium for Political and Social Research (ICPSR). A detailed description of the survey 
design and procedure can be found at the ICPSR website. A team of researchers from 
  
40
Harvard Medical School and Harris Interactive designed the survey. Professionals from 
Harris Interactive collected the data.  A 20-minute telephone interview was conducted with 
a nationally representative sample of 3000 adults between July 5, 2001 and January 16, 
2002 (Weissman, 2003).  The unit of analysis was adults aged 18 and older living in the 
continental United States and having telephones. The questionnaire included 179 questions 
focusing on five categories:  
            The first category was health status and utilization. Respondents were asked about 
their overall health, the estimated time since their last physician visit, whether they were 
currently taking any prescription drugs, from what sources and how often they received 
medical information, and which health information resource was most important to the 
respondents.   
            The second category was experience with DTC advertising, including questions on 
the media in which they had seen drug advertisements, whether their friends had 
mentioned advertisements to them, and whether the advertisements had provided useful 
information. 
            The third category was visits to physicians to discuss information. Respondents 
were questioned on whether advertisements had ever prompted them to talk to their 
physicians about a prescription drug, a new health condition, or a possible change in 
treatment for an ongoing concern. 
            The fourth category was outcomes of visit, such as whether the drug prescribed by 
their physician was the same drug they had seen in advertisement, did they fill or take the 
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prescription that their physician prescribed, and their satisfaction with the drug’s 
performance if they filled the prescription.            
 The last category included background information: gender, age, race, marital status, 
insurance coverage for prescription drugs, education, employment status, and income. 
 
 
Sample design 
             The sample was selected through computerized random digit dialing (RDD). RDD 
ensured that the sample included not only those persons whose telephone numbers were 
listed in telephone directories but also those whose numbers were not listed (Weissman, 
2003). The researchers used a stratified sampling process. This sample design based the 
number of persons in each stratum of the sample on the proportion of the stratum in the 
total population (Babbie, 1990). It ensured proper representation of enrollees in different 
regions of America. The adjusted response rate was 58 percent. The survey data were 
weighted by age, race, education, health insurance status (insured or uninsured), household 
size and gender to reflect the demographic composition of U.S. population. This sample 
was demographically similar to the U.S. population as described in the March 2001 
Current Population Survey from the U.S. Census Bureau (Weissman, 2003). 
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Survey Procedures 
            A computer-assisted telephone interviewing system (CATI) was used for on-line 
data entry and editing of telephone interviews. The interview process was flexible. It 
varied depending on whether a respondent had seen or heard a DTC advertisement, talked 
to a physician about information presented in a DTC advertisement, and based on the 
outcomes of the discussion (receiving a prescription, filling the prescription and taking the 
drug as prescribed). For example, if a participant had not seen any advertisements or been 
told about an advertisement by a friend or a relative, no question was asked about 
physician visits or visit outcomes. Instead, CATI would skip to the next relevant question 
(Weissman, 2003). A number of methods were used to maximize the response rate. A $10 
incentive was offered for completion of the interview. Two dollars were mailed to 
nonrespondents as an additional incentive.  Nonrespondents were also sent a letter 
explaining the purpose of the survey and encouraging them to participate. Attempts were 
made to contact nonrespondents at various times of the day and days of the week. 
Researchers also set up a toll-free number that respondents could call to complete the 
survey at a convenient time (Weissman, 2003). 
 
 
Variables in conceptual framework  
Dependent variables              
            The conceptual framework specified three outcome variables as a result of DTC 
advertising:  visit for prescription drug, visit for new condition, and visit for treatment 
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change.  Only those who had seen or heard an advertisement for a prescription drug in the 
past 12 months were asked about their physician visits. Rather than using a single 
dependent variable, we used three dependent variables to measure DTC-prompted visits. 
One of the advantages was that it offered a comprehensive overview of physician visits for 
different purposes.  Another advantage was that it helped identify the strongest predictors 
of DTC-prompted visits. For instance, if a factor or an independent variable was found to 
be related to all three dependent variables, it was probably a strong predictor of DTC-
prompted visit.  In contrast, if a factor or an independent variable only showed significant 
association with one dependent variable, it was probably a weaker predictor than the 
former one.  
 
Visit for prescription drug:            
           Visit for prescription drug was defined as whether an advertisement for a 
prescription drug ever prompted the respondent to talk to a physician about a prescription 
drug for themselves. If the person responded “yes”, the variable “visit for prescription drug 
” was given a value of one. If the answer was “no”, then the variable was given a value of 
zero.  
 
Visit for new condition: 
            Visit for new condition was defined as whether an advertisement for a prescription 
drug ever prompted a respondent to talk to a physician about a medical condition, illness, 
or other health concern of their own that they had not discussed with a physician before. If 
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the person responded “yes”, the variable “visit for new condition” was given a value of 
one. If the answer was “no”, then it was given a value of zero.  
 
Visit for treatment change: 
            Visit for treat change was defined as whether an advertisement for a prescription 
drug ever prompted the respondent to talk to a physician about a possible change in 
treatment for a medical condition or illness that he or she already had. If the person 
responded “yes”, the variable “visit for treatment change” was given a value of one. If the 
answer was “no”, then it was given a value of zero.  
 
 
Independent variables 
             The independent variables were grouped into five factors: personal beliefs, 
demographics, socioeconomics, health status, and market factors.  
 
Personal beliefs  
             The personal beliefs consisted of variables identified from the two behavioral 
theories. Variables from four subgroups were included in the personal belief factor. They 
were subjective norm (two variables: source importance and source utilization), perceived 
benefit (two variables: awareness of treatments and patient-physician communication), 
perceived barrier (two variables: unbalanced information in DTC advertisements and 
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physician’s authority), and perceived severity (self-reported overall health). The following 
questions were used to measure respondents’ personal  beliefs. 
 
Subjective norm 
             Source utilization: “How often do you get information about health from?” 
(TV/radio, internet, newspapers or magazines, family and friends, a pharmacist, pamphlets 
in a physician’s office, or a physician) (Weissman, 2003) 
             Respondents were asked about their utilization of each source of information: 
television or radio (not including advertisements), Internet websites, newspapers or 
magazines (not including advertisements), family and friends, a pharmacist, pamphlets in a 
physician’s office or waiting room, and physicians. Responses for the utilization of each 
source were measured with: 1 = never, 2 = hardly ever, 3 = sometimes, and 4 = often. 
Referent source:  “Which one of the sources was the most important in prompting you to 
talk to your physician?” (Weissman, 2003) 
   For this question, we classified the above sources/referents into two categories: 
media source or non-media source.  Media sources included television or radio, Internet 
websites, newspaper or magazine, pamphlets and advertisements for prescription drug.  
The remaining sources were defined as non-media sources. If a person chose a media 
source, the variable “referent source” was given a value of one. If the choice was non-
media source, then variable was given a value of zero. 
 
Perceived benefit 
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           Awareness of treatments: “(DTC advertisements) made me aware of a treatment or 
of treatments that I did not know about.” (Weissman, 2003) 
           Patient-physician communication: “(DTC advertisements) helped me to have better 
discussions about my health with a health professional.” (Weissman, 2003) 
            Responses to both questions were measured with 4-point likert scales: 1= strongly 
disagree, 2= agree, 3= disagree, 4 = strongly disagree. 
 
Perceived barrier 
             Unbalanced information: “(DTC advertisements) did not provide information on 
risks and benefits in a balanced manner.” (Weissman, 2003) 
             Physician’s authority: “(DTC advertisements) made me less confident in my 
physician’s judgment.” (Weissman, 2003) 
             The answers to questions about unbalanced information and physician’s authority 
were also measured with 4-point likert scales: 1= strongly disagree, 2= agree, 3= disagree, 
4 = strongly disagree. 
 
Perceived severity 
              “Overall health: overall, how would you describe your health?” (Weissman, 2003) 
               Five categories were used to measure overall health: 1 = poor, 2 = fair, 3 = good, 
4 = very good, and 5 = excellent.  The literature indicated that those who reported they 
were in fair or poor health were more likely to talk to their physician about advertised 
drugs, though not more likely to receive a prescription for the medicine (Kaiser, 2001).  
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Socioeconomic factors 
              The socioeconomic factors included education, income and prescription insurance 
coverage.  
 
Education:  
              Five levels were used to measure education: less than high school graduate (coded 
1), high school graduate or equivalent (coded 2), completed some college, but no degree 
(coded 3), college graduate (code 4), graduate school level and above (coded 5). Education 
has been identified as an important factor to predict patients’ attitude toward DTC 
advertising. According to Gonul, educated consumers were less likely to trust prescription 
drug advertisements (Gonul, 2000). We assumed education level has an impact on DTC-
prompted visits.   
 
Income: 
              Income was coded as: 1 = income less than $15000, 2 = income above or equal to 
$15000 and less than $30000, 3 = income above or equal to $30000 and less than $75000, 
and 4 = income above or equal to $75000.  There was no literature indicating that income 
has an impact on patient’s experience of talking with a physician about advertised 
prescription drugs. However, studies have reported that income plays an important role in 
the patient’s medical decision making. For instance, higher income groups were more 
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likely to use prescription drugs for their conditions as compared to lower income groups 
(Stuart, 1998); and for Medicaid beneficiaries, even small increases in co-pay for 
“essential” medications could have substantial unintended effects, such as sharp increases 
in ER visits and outpatient visits because of non-compliance (Soumerai, 1994). 
 
Prescription insurance coverage: 
              Prescription coverage was coded as: 1 = all prescription expenditures are covered 
by insurance, 2 = some prescription expenditures are covered by insurance, and 3 = no 
prescription expenditures are covered by insurance.  Advertised prescription drugs were 
usually more expensive than non-advertised drugs (Kaiser, 2001). Patients had to pay more 
out of pocket for advertised drugs if they did not have our only had limited prescription 
drug coverage, which might deter them from visiting their physicians to discuss an 
advertised prescription drug.  A former study has shown that restriction in prescription 
drug coverage has a significant impact on prescription decisions among vulnerable 
populations (Soumerai, 1994). We did not include insurance coverage as a predictive 
variable because normally when a patient has prescription drug coverage they also have 
coverage for hospital and medical expenses.  Putting both insurance variables in a 
regression model might introduce multicollinearity (Field, 2003). 
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Health status factors 
             Health status factors consist of disease conditions, medication use, and healthcare 
service utilization. 
 
Disease conditions: 
             In this study, we attempted to explore how different disease conditions interacted 
with DTC advertising to influence patients’ physician visit behavior. Seven chronic 
conditions were included in the survey and considered for analysis: diabetes, arthritis, 
allergy, high cholesterol, depression, asthma and anxiety. For each chronic condition, 
respondents were asked whether a physician or another health professional had told them 
that they had the condition.  If they responded “yes”, the variable for that disease condition 
was given a value of one. If the answer was “no”, then that variable was given a value of 
zero.  
            No study has investigated how having a particular disease condition would affect 
one's likelihood of visiting a physician for an advertised drug. We chose the seven chronic 
disease conditions for study because drugs treating these conditions have been heavily 
advertised over the years.  Examples included Lipitor for high cholesterol, Zoloft for 
depression, Claritin for allergy, and Vioxx for arthritis.  
 
Medication use  
             Medication use was defined by whether or not respondents were taking any 
prescription drugs on a regular basis. If they responded “yes”, the variable “medication 
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use” was given a value of one. If the answer was “no”, then the variable was given a value 
of zero.  We assumed that patients who were on their medications on a regular basis were 
normally concerned with their treatments and visited their physician regularly and, 
therefore, had more chance to ask their physicians about advertised prescription drugs.  
 
Healthcare service utilization 
             Healthcare service utilization was assessed as the frequency of physician visits. 
Participants were asked how long it had been since the last time they visited a physician 
for non-emergency purposes. The responses to this question included: within the last three 
months (coded 1), more than three months but less than one year ago (coded 2), and more 
than one year ago (coded 3). We supposed that patients who use healthcare services 
frequently have more chances to talk with their physicians about DTC advertisements than 
those who seldom visit a physician. They thereby were assumed to be more likely to visit 
their physician for an advertised prescription drug.   
 
 
Market factors 
            Market factors were marketing influences on patients when they were exposed to 
advertisements in mass media campaigns for prescription drugs. Market factors consisted 
of advertisement attentiveness and advertisement information utilization.  
 
Advertisement attentiveness: 
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            Advertisement attentiveness was defined as patient’s attentiveness to DTC 
advertisements. Since the survey did not include a direct measure of advertising 
attentiveness, we constructed a proxy variable for this measure. We assumed that those 
patients having chronic conditions treatable with advertised drugs would be more attentive 
to DTC advertisements for those drugs; healthy patients or those without the condition 
would not be interested in the information. Minitz’s study has indicated that patients with 
conditions potentially treatable by advertised drugs were more likely to request advertised 
drugs (Minitz, 2003). We further assumed that patients’ advertisement attentiveness 
increased with DTC spending on drugs treating their diseases. Thus, the proxy value of 
“advertisement attentiveness” for each respondent was based on the DTC spending on the 
drugs used to treat the respondent’s chronic conditions. 
DTC spending data were available from National Institutes of Health Care Management 
(NIHCM) annual DTC advertising report. According to the report, the top 50 most heavily 
advertised drugs accounted for 95 percent of total DTC spending in 2000 (NIHCM, 2001). 
The DTC spending on the top 50 drugs were classified into different therapeutic categories, 
including anti-arthritis, anti-depressant, lipid lowering, anti-anxiety, anti-diabetes, and 
other categories (NIHCM, 2001). Drugs for treating acute diseases were excluded from this 
study because DTC spending on these drugs was less than 5%, the impact of which could 
be neglected for this study (NIHCM, 2001).  
            For each of the seven chronic conditions (diabetes, arthritis, allergy, high 
cholesterol, depression, asthma, and anxiety), we first coded each chronic condition for 
each respondent as a dummy variable (0 = without this condition, 1 = with this condition) 
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We then weighted the dummy variable with annual DTC spending on drugs treating this 
chronic condition. In some cases, a respondent may have had more than one chronic 
condition. For instance, if a respondent reported having three chronic diseases, the 
estimated value of his or her “advertisement attentiveness” can be inferred from the sum of 
DTC spending on drugs for the three diseases. The calculation formula was as follows: 
             f (x) = ∑ βk x (x = dummy, k = 1,2,…,7)     
             β = DTC spending on drugs for each chronic condition in 2000 
We then used SPSS’s “categorize variables” function to convert continuous numeric data 
to a discrete number of categories. After ranking cases in ascending order, data were 
categorized based on percentile groups, with each group containing approximately the 
same number of cases. In our study, a specification of four categories (1 = very low, 2 = 
low, 3 = high, 4 = very high) would assign a value of 1 to cases below the 25th percentile, 
2 to cases between the 26 th and 50th percentile, 3 to cases between the 51st and 75th 
percentile, and 4 to cases above the 75th percentile. We used this new variable as a proxy 
variable to estimate the patients’ attentiveness to DTC advertisements. 
 
 Advertisement information utilization 
            Advertisement information utilization was measured by asking how often patients 
get information about health care from advertisements on TV and radio, in newspapers or 
magazines.  Responses were coded as: 1 = never, 2 = hardly ever, 3 = sometimes, and 4 = 
often. We expected that advertisement information utilization was positively associated 
with physician visits as a result of DTC advertising. 
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Demographic factors 
            Demographic factors were another component of the conceptual framework 
constructed in this study.  They consisted of sex, age, race, and marital status.  
 
Age  
            Age was self-reported by respondents during the survey.  Studies showed that 
patients’ responses to DTC advertisement varied with age (Doucette et al., 1998; Gonul et 
al., 2000; Kaiser, 2001). Older consumers were less likely to report a desire to seek 
additional information, such as talking to a physician after exposure to a DTC 
advertisement. It was reported that older consumers were more likely to trust their 
physician instead of advertisement (Gonul et al., 2000). We assigned respondents to three 
age groups: 18 to 34 (coded 1), 35 to 64 (coded 2), 65 and older (coded 3).  
 
Gender 
            Gender was coded one for male and zero for female. Pyrot found women were 
more likely to request an advertised prescription drug than men were.  However, when his 
model adjusted for attitudes and exposure to DTC advertisements, no difference was found 
between genders (Pyrot, 1998). 
 
Race: 
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            In this study, race was coded one for white, two for black and three for other race. 
A former study indicated that whites were more likely to request an advertised prescription 
drug than nonwhites in the univariate analysis (Pyrot, 1998). When the model was adjusted 
for attitudes and exposure to DTC advertisements, no difference was found among races.  
 
Marital status 
            Marital status was coded as one for single respondents and as zero for non-single 
respondents. Single respondents included divorced, separated, widowed, single and never 
married. Non-single respondents included married and living with a partner.  
 
          
Intervention 
            The intervention in this study was whether a patient had seen or heard an 
advertisement for a prescription drug in the past 12 months. Respondents were required to 
answer with “yes” or “no”. The interventional variable was not added to the regression 
analysis because only those who had seen or heard an advertisement for a prescription 
drugs in the past 12 months were asked about their physician visits.  
            The variables, including three dependent variables and all independent variables 
used in this study were presented in Table 3.  
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Data analysis 
             Statistical analyses were performed with SPSS 11.5 for Windows (SPSS, 2002). 
We first conducted descriptive analysis on the predictive and dependent variables to 
understand each variable’s characteristics and distribution. We then conducted simple 
bivariate logistic regression analysis to determine strength and direction of relationship 
between each independent variable and the dependent variables. The independent variables 
with a weak or without association with the dependent variables were excluded from the 
logistic regression models to reduce multicollinearity and simplify the models.  We also 
examined the strength of association among independent variables to identify variables that 
were highly correlated, so that we could take appropriate measures to address the problem 
of muticollinearity. 
 
Multicollinearity 
            Multicollinearity was an important issue that needed to be addressed because over 
25 predictive variables were added to each regression model. Multicollinearity was a result 
of strong correlation between independent variables. The existence of multicollinearity 
may result in inflation of parameter (coefficient) estimates and consequently incorrect 
conclusions about the relationship between independent and dependent variables (Field, 
2003). Thus, we performed co-linearity diagnostics among the independent variables to 
examine their tolerance and values of variance inflation factor (VIF).  Tolerance values 
ranged between zero and one and indicated how much variability of one independent 
variable cannot be explained by other independent variables in the model. The variance 
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inflation factor (VIF) was 1/Tolerance. It was the degree of inflation in the variances of the 
parameter (coefficient) estimates due to multicollinearity among the independent variables. 
There was no gold standard for the cutoff value when using VIF for determining the 
presence of multicollinearity. In this study, values of VIF exceeding 10.0 were regarded as 
indicating multicollinearity (Greene, 1997). 
  
Multivariate analyses 
              Three multivariate logistic regression models were constructed to test the effects 
of the predictive factors in our model on DTC-prompted visits. Just like linear regression, 
logistic regression gives each regressor a coefficient or parameter estimator β 1 which 
measures the regressor's independent contribution to variations in the dependent variable.  
In a logistic regression, the dependent variable is a binary variable with values of 0 and 1. 
The advantage of logistic regression is that it makes no assumptions about the distribution 
of the independent variables. They do not have to be normally distributed or of equal 
variance within each group (Lattin at el., 2003; Field, 2003). The relationship between the 
predictor and response variables was not a linear function in logistic regression. Instead, 
the logistic regression function was used, which was the logit transformation of θ: 
                                                 
            An alternative form of the logistic regression equation is: 
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                 In the above model, the logit transformation of θ on the left side of the function 
stands for the logit transformation of dependent variable (visit for prescription drug, or 
visit for new condition, or visit for treatment change). The variables x1 …. xk  represent 
each of the independent variables from five groups of factors. We included different 
independent variables from five groups of factors (personal beliefs, demographic factors, 
socioeconomic factors, health status factors and market factors) in each logistic regression 
model.  α is the constant of the equation. β1 … β i is the coefficient of each independent 
variable. Our hypothesis was that β 1 = β 2 = β 3…= β i = 0, which assumed that there is 
no statistically significant relationship between each independent variable and the 
dependent variables (visit for prescription drug, or visit for new condition, or visit for 
treatment change). 
                In the logistic regressions, Wald chi-square tests were conducted to test the 
significance level of each regressor. Reference groups were used when the categorical 
variables had more than two categories or levels. Usually the reference group is the lowest 
level.  
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CHAPTER 4 
RESULTS 
 
            In Chapter 3, we discussed the data sources used for the study, operationalized the 
dependent and independent variables, and described statistical procedures for analyses. In 
this chapter, we will present the study results.  
 
1. Descriptive analyses 
            The characteristics of respondents are presented in Table 5. Among the 
respondents, 48% were females and 80% were white. Most respondents were between 35 
and 64 years of age with annual income of $30,000 or more.  Most were fully or somewhat 
covered with prescription drug insurance (including Medicare or Medicaid), but 20% of 
respondents had no prescription insurance coverage. This sample of 3000 respondents was 
demographically similar to the U.S. population as described in the March 2001 Current 
Population Survey from the U.S. Census Bureau (Weissman, 2003). The descriptive 
analysis of dependent variables and the intervention are listed in Table 6. In the past 12 
months, 86% of respondents had seen or heard an advertisement for prescription drugs. 
Among the respondents, 27% had been prompted talk to a physician about a prescription 
drug for themselves; 16% had been prompted to talk about a new health condition of their 
own; 17% had been prompted to ask their physician about a possible change to new 
treatment.   
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2. Multicollinearity 
            We ran multicollinearity tests to examine the relationships between independent 
variables. We wanted to find how much variability of one independent variable can be 
explained by other independent variables in the model. If other independent variables can 
explain most of the variance of an independent variable, there exits multicolinearity 
between this independent variable and other ones. The existence of multicollinearity may 
result in inflation of coefficient estimates in multivariate models, and consequently 
incorrect conclusions about the relationship between the independent and dependent 
variables (Field, 2003). One way to deal with multicollinearity is to exclude one of each 
pair of highly correlated independent variables from the multivariate regression model 
(Field, 2003) In this study, a value of the variance inflation factor (VIF) exceeding 10 was 
regarded as an indication of multicollinearity (Greene, 1997; Field et al., 2000). Co-
linearity diagnostic tests showed that most independent variables’ VIF values were lower 
than 3. (See Table 7.) The exception was “advertisement attentiveness” (VIF = 6.28).  Its 
VIF was higher than 3, but still lower than the cutoff value of 10. Since no apparent 
multicollinearity was found among the independent variables, the parameter estimates 
(coefficients) in the logistic regression models was unlikely to be inflated.  
 
 
3. Outcomes on visit to discuss prescription drug 
3.1. Bivariate analyses 
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             The purpose of the bivariate analysis was to identify the strength and direction of 
the association between the dependent variable (“visit for prescription drug”) and 
individual independent variables. If we found there was no or very weak association 
between the dependent variable and an independent variable, the particular variable would 
be excluded from the multivariate regression model in order to reduce multicollinearity and 
simplify the models. We used a cutoff value of p = 0.25 (Hosmer et al., 2000). Since the 
dependent variable and independent variables were categorical, we ran Pearson chi-square 
tests to examine the relationship between the dependent variable and each independent 
variable. Bivariate analyses showed that marital status was not associated with visit for 
prescription drug (p = 0.85). Hence, marital status was excluded from the multivariate 
analysis. All other independent variables were associated with visit for prescription drug. 
The results of Pearson chi-square tests were shown in Table 8. 
 
3.2 Mutivariate analysis 
3.2.1. Model evaluation 
            Stepwise logistic regression was conducted to determine which independent 
variables were predictors of visit for prescription drug. After running stepwise logistic 
regression, only nine variables stayed in the model. The variables with significant effects 
are listed in Table 9.  Hosmer and Lemeshow’s Goodness-of-fit test statistic (Hosmer et 
al., 2000) was much greater than 0.05 (p= 0.863). This suggested no significant difference 
between the observed and model-predicted values of the dependent variable. Therefore, the 
model’s estimates fitted the data at an acceptable level. Regression results indicated the 
  
61
overall model was statistically reliable in distinguishing between visit for prescription drug 
and no visit for prescription drug. (-2 log Likelihood  = 1888.73; Chi-square = 797.1, df = 
19, p < 0.0001). The model correctly classified 93.8% of those in the “no visit” and 48.5% 
of those in the “visit” category. 
 
3.2.2 Model outcomes for research hypothesis: H1 and H2 
            The first hypothesis of this study was that there was a statistically significant 
relationship between patients’ individual characteristics and whether or not they would talk 
with their physician about a prescription drug prompted by DTC advertisement. The 
second hypothesis of this study was that there was a statistically significant relationship 
between patients’ personal beliefs and whether or not they would talk with their physician 
about a prescription drug prompted by DTC advertisement. We used “visit for prescription 
drug” as the dependent variable and variables from the five groups of factors 
(demographics, socioeconomics, health status, market factor, and personal belief) as 
independent variables to test the two hypotheses. The findings of logistic regression 
analyses are presented as follows (see Table 9). 
 
a. Effect of demographic factors 
            We found no evidence of association between visit for prescription drug after 
seeing or hearing a DTC advertisement and any demographic factors (race, gender, age, 
and marital status).   
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b. Effect of socioeconomic factors 
            We also found no evidence of association between visit for prescription drug after 
seeing or hearing a DTC advertisement and any socioeconomic factors (income, education, 
and prescription drug coverage).   
 
c. Effect of health status factors 
            The odds of visiting for prescription drug for patients on regular medications were 
1.6 times as high as the odds for those who were not on regular medications (p < 0.0001). 
Patients with depression (p = 0.016) and patients with anxiety (p = 0.028) were more likely 
to visit to discuss prescription drug after seeing or hearing a DTC advertisement than those 
without such disease conditions. (Table 9.) 
 
d. Effect of personal beliefs 
            Three variables measuring subjective norms showed significant associations with 
the dependent variable (“visit for prescription drug”). Two of these variables measured 
information source utilization. We found that visiting for prescription drug after seeing or 
hearing a DTC advertisement was associated with the frequency of getting health 
information from a physician. Specifically, a patient who often (p = 0.009) consulted a 
physician had a higher chance to visit for prescription drug than those who never did so. 
Patients who often (p = 0.014) or sometimes (p = 0.006) consulted a pharmacist had a 
higher chance to be prompted by DTC advertisements to visit their physician to discuss a 
prescription drug than those who never consulted a pharmacist. The odds of visiting for 
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prescription drug for patients who viewed media as the most important source prompting 
them to talk with their physician were almost 11 times as high as those who did not. (p < 
0.0001) (Table 9.) 
            Patients’ attitudes towards DTC advertising demonstrated strong association with 
their behaviors of visiting for prescription drug. Those who somewhat agreed (p < 0.0001) 
or strongly agreed (p < 0.0001) that DTC advertisements increased awareness of new 
treatment were much more likely to visit to discuss prescription drugs than those who 
strongly disagreed. At the same time, the odds of another perceived benefit, better 
discussion with health professionals, were also significantly different between the 
somewhat agree/strongly-agree groups and the strongly-disagree group. Those who 
somewhat agreed (p < 0.0001) or strongly agreed (p < 0.0001) were more likely to visit for 
prescription drug after seeing or hearing a DTC advertisement than those who strongly 
disagreed.  
            No evidence of association was found between visit for prescription drug after 
seeing or hearing a DTC advertisement and perceived barrier or perceived severity. (Table 
9.) 
 
e. Effect of market factors 
            Advertisement attentiveness was strongly associated with the dependent variable 
(“visit for prescription drug”). (p < 0.0001) In this study, patients with a high level of 
advertisement attentiveness were defined as those who suffered from multiple chronic 
conditions that have attracted substantial DTC advertising expenditure. Patients with high 
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(p = 0.003) or very high (p < 0.0.001) advertisement attentiveness were more likely to visit 
their physician for prescription drug after seeing or hearing a DTC advertisement than 
those with very low advertisement attentiveness. (Table 9.) 
 
3.2.3 Summary of model results for hypothesis: H1 and H2 
          The results of the logistic regression analysis supported our first hypothesis that 
there was a statistically significant relationship between patients’ individual characteristics 
and whether or not they would talk with their physician about a prescription drug prompted 
by DTC advertisement. Specifically, patients on regular medications, patients with 
depression or anxiety, or patients with high advertisement attentiveness were more likely 
to visit their physician to discuss a prescription drug after seeing or hearing DTC 
advertisements. The results of the regression analysis also supported our second hypothesis 
that there was a statistically significant relationship between patients’ personal beliefs and 
whether or not they would talk with their physician about a prescription drug prompted by 
DTC advertisement. Patients who viewed media as the most important source prompting 
them to talk with their physician, patients who often got health information from a 
physician or a pharmacist, and those who had positive attitudes towards DTC 
advertisements were more likely to visit their physician to discuss a prescription drug as a 
result of DTC advertisements. 
 
 
4. Outcomes on visit to discuss new health condition 
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4.1. Bivariate analyses 
            Pearson chi square analyses showed that race, marital status, income, prescription 
drug coverage, and diabetes were not associated with visit for new condition. Hence, these 
five variables were excluded from multivariate analyses. All other independent variables 
were associated with the dependent variable. The results of Pearson chi-square tests were 
shown in Table 8. 
 
4.2 Mutivariate analyses 
4.2.1. Model evaluation 
           After running stepwise logistic regression, only eight variables stayed in the model. 
The variables with significant effects were listed in Table 10. Hosmer and Lemeshow’s 
Goodness-of-fit test statistic (Hosmer et al., 2000) was much greater than 0.05 (p= 0.51). It 
suggested no significant difference between the observed and model-predicted values of 
the dependent variable. Therefore, the model’s estimates fitted the data at an acceptable 
level. Regression results indicated the overall model was statistically reliable in 
distinguishing between visit for new condition and no visit for new condition. (-2 log 
Likelihood = 1699.66; Chi-square = 493.9, df = 18, p < 0.0001). The model correctly 
classified 96.5% of those in the “no visit” and 23.9% of those in the “visit” category.  
 
4.2.2 Model outcomes for research hypothesis: H3 and H4 
           The third hypothesis of this study was that there was a statistically significant 
relationship between patients’ individual characteristics and whether or not they would talk 
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with their physician about a new health concern prompted by DTC advertisement. The 
fourth hypothesis of this study was that there was a statistically significant relationship 
between patients’ personal beliefs and whether or not they would talk with their physician 
about a new health concern prompted by DTC advertisement. We used “visit for new 
condition” as the dependent variable and variables from the five groups of factors 
(demographics, socioeconomics, health status, market factor, and personal belief) as 
independent variables to test the two hypotheses. The findings of logistic regression 
analyses are presented as follows: (see Table 10.) 
 
a. Effect of demographic factors 
           We found no evidence of association between visit for new condition after seeing or 
hearing a DTC advertisement and any demographic factors (race, gender, age, and marital 
status).   
 
b. Effect of socioeconomic factors 
           We also found no evidence of association between visit for new condition after 
seeing or hearing a DTC advertisement and any socioeconomic factors (income, education, 
and prescription drug coverage).   
 
c. Effect of health status factors 
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            Patients with arthritis (p < 0.0001) and patients with anxiety (p < 0.0001) were 
more likely to visit for new condition after seeing or hearing a DTC advertisement than 
those without such disease conditions. (Table 10.) 
 
d. Effect of personal beliefs 
            There were three variables measuring subjective norms that showed significant 
effects on the dependent variable (“visit for new health condition”). Two variables 
measured information source utilization. We found that visiting for new condition after 
seeing or hearing a DTC advertisement was associated with the frequency of getting health 
information from a pamphlet in a physician's office or waiting room (p < 0.0001).  
Specifically, patients who often (p < 0.0001) got health information from pamphlets had a 
higher chance to visit their physician for new condition than those who never did so. 
Visiting for new condition after seeing or hearing a DTC advertisement was also 
associated with the frequency of getting health information from family and friends (p = 
0.02).  However, no significant differences were found between the “never” group and any 
other groups. Odds of visiting for new condition for the patients who viewed media as the 
most important source prompting them to talk with their physician were almost 5 times as 
high as those who did not. (p < 0.0001) (Table 10.) 
            Patients’ attitudes towards DTC advertising demonstrated strong association with 
their behaviors of visiting for new condition. Those who somewhat agreed (p = 0.001) or 
strongly agreed (p < 0.0001) that DTC advertisements increased awareness of new 
treatments were much more likely to visit for new condition than those who strongly 
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disagreed. At the same time, the odds of another perceived benefit, better discussion with 
health professionals, were also significantly different between the somewhat 
agree/strongly-agree groups and the strongly-disagree group. (p < 0.0001)  Those who 
somewhat agreed (p < 0.0001) or strongly agreed (p < 0.0001) were much more likely to 
visit for new condition after seeing or hearing a DTC advertisement than those who 
strongly disagreed. Moreover, believing that DTC advertisements did not provide 
information on risks and benefits in a balanced manner was negatively associated with 
patient’s health behavior of visiting for new condition. (p = 0.037).  However, no 
significant differences were found between the strongly-disagree group and any other 
groups. No evidence of association was found between visit for new condition after seeing 
or hearing a DTC advertisement and perceived severity. (Table 10.) 
 
e. Effect of market factors 
            There was no evidence of association between visit for new condition after seeing 
or hearing a DTC advertisement and advertisement attentiveness. 
 
4.2.3   Summary of model results for hypothesis: H3 and H4 
           The results of the logistic regression analysis supported our third hypothesis that 
there was a statistically significant relationship between patients’ individual characteristics 
and whether or not they would talk with their physician about a new health concern 
prompted by DTC advertisement. Specifically, patients with arthritis or anxiety were more 
likely visit their physician to discuss a new health concern after seeing or hearing DTC 
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advertisements. The results of the regression analyses also supported our fourth hypothesis 
that there was a statistically significant relationship between patients’ personal beliefs and 
whether or not they would talk with their physician about a new health concern prompted 
by DTC advertisement. Patients who viewed media as the most important source 
prompting them to talk with their physician, patients who often got health information 
from family and friends, or from a pamphlet in a doctor’s office or waiting room, and those 
who had positive attitudes towards DTC advertisements were more likely to visit their 
physician to discuss a new health concern as a result of DTC advertisements. 
 
 
5. Outcomes on visit to discuss treatment change 
5.1. Bivariate analyses 
          Pearson chi square analyses showed that marital status and income were not 
associated with visit for treatment change. Hence, marital status and income were excluded 
from multivariate analyses. All other independent variables were associated with the 
dependent variable (Table 8). 
 
5.2 Mutivariate analyses 
5.2.1. Model evaluation 
          After running stepwise logistic regression, ten variables stayed in the model (Table 
11). Hosmer and Lemeshow’s Goodness-of-fit test statistic (Hosmer et al., 2000) was 
much greater than 0.05 (p= 0.80). Regression results indicated the overall model was 
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statistically reliable in distinguishing between visit for treatment change and no visit for 
treatment change. (-2 log Likelihood = 1621.48; Chi-square = 606.50, df = 23, p < 0.0001). 
The model correctly classified 96.8% of those in the “no visit” and 32.1% of those in the 
“visit” category.  
 
5.2.2 Model outcomes for research hypothesis: H5 and H6 
          The fifth hypothesis of this study was that there was a statistically significant 
relationship between patients’ individual characteristics and whether or not they would talk 
with their physician about change in treatment prompted by DTC advertisement. The sixth 
hypothesis of this study was that there was a statistically significant relationship between 
patients’ personal beliefs and whether or not they would talk with their physician about 
change in treatment prompted by DTC advertisement. We used “visit for treatment 
change” as the dependent variable and variables from five groups of factors 
(demographics, socioeconomics, health status, market factor, and personal belief) as 
independent variables to test the two hypotheses. The findings of logistic regression 
analyses are presented as follows. (see Table 11.) 
 
a. Effect of demographic factors 
            Race was the only demographic factor associated with patient’s visit for treatment 
change. Visits for treatment change were more likely to happen among black patients than 
among patients of races other than black or white. (p = 0.001). No difference was found 
between white patients and those from other races. (Table 11.) 
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b. Effect of socioeconomic factors 
            We found no evidence of association between visit for treatment change after 
seeing or hearing a DTC advertisement and any socioeconomic factors (income, education, 
and prescription drug coverage).   
 
c. Effect of health status factors 
            The odds of visit to discuss treatment change for patients on regular medications 
were 2.1 times as high as the odds for those who were not on regular medications (p < 
0.0001). Patients with anxiety (p = 0.003) were more likely to visit for treatment change 
after seeing or hearing a DTC advertisement than those without anxiety. (Table 11.) 
 
d. Effect of personal beliefs  
            There were three variables measuring subjective norms that showed significant 
effects on the dependent variable (“visit for treatment change”). Two variables measured 
information source utilization. We found that visit for treatment change after seeing or 
hearing a DTC advertisement was associated with the frequency of getting health 
information from Internet websites (p = 0.037). Specifically, patients who often (p = 0.008) 
searched Internet web sites for health information were more likely to visit their physician 
for treatment change than those who never did so. Patients who often (p = 0.004) or 
sometimes (p = 0.044) consulted a pharmacist were more likely to be prompted by DTC 
advertisements to visit their physician for treatment change than those who never consulted 
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a pharmacist. The odds of visiting for treatment change for patients who viewed media as 
the most important source prompting them to talk with their physician were almost 5 times 
as high as those who did not. (p < 0.0001) (Table 11.) 
            Patients’ attitudes towards DTC advertising demonstrated strong association with 
their behaviors of visiting for treatment change. Those who somewhat agreed (p = 0.029) 
or strongly agreed (p = 0.0001) that DTC advertisements led to increased awareness of 
new treatment were much more likely to visit for treatment change than those who strongly 
disagreed. At the same time, the odds of another perceived benefit, better discussion with 
health professionals, were also significantly different between the somewhat 
agree/strongly-agree group and the strongly-disagree group. (p < 0.0001) Specifically, 
those who somewhat agreed (p < 0.0001) or strongly agreed (p < 0.0001) were much more 
likely to visit for treatment change after seeing or hearing a DTC advertisement than those 
who strongly disagreed. (p < 0.0001). Moreover, believing that DTC advertisements made 
one less confident with physician’s judgment was negatively associated with the patients’ 
health behavior of visiting for new condition. (p = 0.034).  However, a significant 
difference only showed between strongly-disagree group and somewhat-agree group. (p = 
0.007) No evidence of association was found between visit for treatment change after 
seeing or hearing a DTC advertisement and perceived severity. (Table 11.) 
 
e. Effect of market factors 
            Advertisement attentiveness was strongly associated with the dependent variable 
(“visit for treatment change”). (p < 0.0001) Patients with high levels of advertisement 
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attentiveness were defined as those who suffered from multiple chronic conditions that 
have attracted substantial DTC adverting expenditure. Patients with high (p < 0.0001) or 
very high (p < 0.0001) advertisement attentiveness were more likely to visit to discuss 
treatment change than those with very low advertisement attentiveness. (Table 11.) 
 
5.2.3   Summary of model results for hypothesis: H5 and H6 
            The results of the logistic regression analysis supported the fifth hypothesis that 
there was a statistically significant relationship between patients’ individual characteristics 
and whether or not they would talk with their physician about change in treatment 
prompted by DTC advertisement. Specifically, patients on regular medications, black 
patients, patients with anxiety, and patients with high advertisement attentiveness were 
more likely to visit their physician to discuss change in treatment after seeing or hearing 
DTC advertisements. The results of the regression analysis also supported our sixth 
hypothesis that there was a statistically significant relationship between patients’ personal 
beliefs and whether or not they would talk with their physician about change in treatment 
prompted by DTC advertisement. Patients who viewed media as the most important source 
prompting them to talk with their physician, patients who often got health information 
from Internet or a pharmacist, and those who had positive attitudes towards DTC 
advertisements were more likely to visit their physician to discuss change in treatment as a 
result of DTC advertisements. 
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CHAPTER 5 
 
DISCUSSION 
 
 
  Based on a conceptual framework, we built three regression models in order to 
identify the strongest predictors of DTC-prompted physician visits. The dependent 
variables of the three regression models were “visit for prescription drug”, “visit for new 
condition”, and “visit for treatment change”. In our study, if an independent variable was 
found to be significantly related to all three dependent variables, it was deemed a strong 
predictor of DTC-prompted visits. The three dependent variables were similar in that they 
measured DTC advertisements’ influence on patients’ physician visit behavior. They 
differed in that they measured physician visits for different purposes 
 
 Strongest predictors of DTC-prompted visits 
We found that out of all independent variables, only five variables consistently 
showed significant effects on the three dependent variables after adjusting for other 
variables. They were: 1) taking medication on regular basis, 2) anxiety, 3) viewing media 
as the most important source prompting one to talk with physician, 4) believing that DTC 
advertisements increased awareness of new treatment, and 5) believing that DTC 
advertisements improved discussion with health professionals. Therefore, these five 
variables were considered to be the strongest predictors for DTC-prompted physician 
visits. 
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 Taking prescription drugs on a regular basis was one of the strongest predictors of 
DTC-prompted visits. It supported the hypothesis that patients with chronic conditions 
potentially treatable by the advertised drugs would be interested in the DTC 
advertisements and visit their physician to request or discuss advertised drugs (Mintzes et 
al., 2003). Anxiety was the only chronic condition showing significant association with all 
types of physician visits, though we also found patients with two other chronic diseases, 
depression and arthritis, were more likely to be prompted by DTC advertisements to visit 
their physician for two of the three types of visits. The results were consistent with other 
research outcomes (Sumpradit, 2002; Mintzes et al., 2003). The significant effects could be 
attributed to the similar characteristics that these disease conditions shared, such as being 
chronic, common, highly symptomatic, troublesome to patients, and treated with drugs 
with high annual spending on DTC advertising (NIHCM, 2001). In addition, anxiety could 
have an additional, psychological effect in influencing patients’ physician visit behavior. 
Patients with anxiety are more likely to worry, especially about their health status. 
Therefore, they would be more sensitive to the symptoms described in the DTC 
advertisements, wondering if they had similar symptoms. As a result, they may be 
prompted to visit their physicians. 
 The major variables adopted from the Theory of Reasoned Action and Health 
Belief Model were strong determinants for each type of DTC-prompted physician visit. 
These personal belief variables included subjective norm, perceived benefit, and perceived 
barrier. In our study, patients who viewed media as the most important source prompting 
them to talk with their physicians were much more likely to visit their physician than those 
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who viewed non-media as more important referent sources. Mintzes also reported similar 
results that those with greater reliance on advertising requested more advertised drugs 
(Mintzes et al., 2003). Two of the other strongest predictors were believing that DTC 
advertisements increased awareness of new treatment (perceived benefit) and believing 
that DTC advertisements improved discussion with health professionals (perceived 
benefit). Our findings agreed with Sumpradit’s study results, which showed positive 
association between positive attitude toward DTC advertisements and consumer’s 
willingness of talk with physicians about advertised drugs (Sumpradit et al., 2002). 
Advertisement attentiveness was significantly related to visit for prescription drug and visit 
for treatment change but not to visit for new condition. Our assumption was that 
advertisement attentiveness exists only when patients have been told by health care 
professionals that they suffer from conditions and when these conditions are potentially 
treatable by advertised drugs.  A new condition is, by definition, one that a patient has not 
yet discussed with a health professional.  So conceptually, visit for new condition would 
not be related with advertisement attentiveness as we measured it.  Because advertising 
attentiveness was significantly related to both visit for prescription drug and visit for 
treatment change, and because conceptually it should not be related to visit for new 
condition, we also deemed advertisements attentiveness as one of the strongest predictors 
for physician visits.              
          This study contributed to the literature of how DTC advertising influenced patients’ 
health behavior in several ways. First, it updated our knowledge about the consequences of 
DTC advertisements, such as physician visits and attitudes towards advertisements. In 
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addition, our study provided a conceptual framework of how DTC advertisements 
influenced patients’ physician visits for different purposes while most previous studies 
only examined one type of physician visit. For instance, Mintzes (Mintzes et al, 2002) and 
Pyrot (Pyrot et al, 1998) analyzed the factors affecting patients’ request behavior but failed 
to address other types of physician visits, such as visit to discuss new health conditions or 
information on prescription drug. Finally, this study tested the conceptual framework with 
a nationally representative sample. Most previous studies were limited in terms of their 
sample size, location, or differences in nationality and healthcare system.  
 
Implications 
             The study had important practical implications to pharmaceutical marketers. Some 
pharmaceutical manufacturers have apparently believed that that selling to the widest 
possible market is the likeliest path to success. However, this “take-all-customers” 
approach was not very productive. It was hard to generate cost effective sales when 
delivering promotional information to the broad audience without targeting individual 
differences. A more efficient way may be to narrow marketing focus and customize 
product messages before disseminating DTC advertisements. Accurate target market 
selection is crucial to productive marketing efforts. To achieve this, a target market must 
be a narrowly defined consumer group consisting of individuals with specialized 
characteristics and having strong desires for what the marketer can offer. DTC advertising 
campaigns may have been less cost-effective because pharmaceutical marketers did not 
aim their efforts at appropriate customer groups.  
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Marketers can use our findings to accurately identify target markets. Our study 
revealed that patients regularly taking medications and those who had anxiety were more 
likely to respond to DTC advertising. Hence, as better potential customers, they could be 
identified as important target markets for specialized DTC advertising. With a higher 
probability of DTC-prompted physicians visits, equal expenditures on marketing 
promotions could achieve higher returns on investments from these patient groups. 
Advertisement attentiveness is a proxy variable based on patients’ chronic 
conditions and annual DTC spending on these conditions. Pharmaceutical companies could 
target more marketing to those consumers who have multiple, heavily advertised chronic 
conditions. Related information could be acquired from medical records, regional or 
national marketing data sources, i.e. IMS or Scott-Levin databases. 
 Personal beliefs about DTC advertisements were also strong predictors for all 
types of physician visit behaviors. According to our findings, patients with positive 
attitudes toward DTC advertisements or patients viewing media as the most important 
source prompting them to talk with physicians were more likely to respond to 
advertisements. Pharmaceutical marketers may be able to identify patients on regular 
medications, those having anxiety, and those with high potential advertisement 
attentiveness from their medical records or pharmacy claims databases. However, it is not 
possible to get information on patients’ personal beliefs from these sources. Therefore, in 
order to target these consumers, pharmaceutical marketers could develop interactive tactics 
to acquire information with advanced Internet technologies. For instance, marketers could 
post personal belief questions on web sites for medical information or pharmaceutical 
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products. They could then develop direct response technologies on the Internet to send 
customized letters and brochures to respondents based on the answers that respondents 
give to questions about their personal beliefs. 
 
Limitations 
             Several limitations should be noted when considering our results.  
             First, we lacked information on how many physician visits each patient had made 
as a result of DTC advertisements and how appropriate or necessary the physician visits 
were. Though Weissman’s study has reported that no worse heath outcomes were found 
among patients who visited their physician for advertised drugs than those who did not, 
further study still needs to examine DTC advertisements’ long-term effects on health 
outcomes (Weissman et al., 2003).    
              Second, our data on medication utilization and health conditions were collected by 
survey. Therefore, they may be subject to self-report bias. However, previous studies have 
evaluated the accuracy and reliability of self-reported medication use and chronic 
conditions. These studies revealed consistency between database information and self-
report results (Boudreau et al. 2003; Brown et al., 1992; West et al., 1995). For example, 
Boudreau’s study explored the accuracy of self-reported use of commonly used 
medications among older women (n = 403). Pharmacy records of statin, antihypertensive, 
and antidepressant medication utilizations were used as the “gold standard” to compare 
with patients’ interview data. Information on the brand name, strength, directions for use 
indications for use, and start and stop dates were collected for comparison. The study 
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showed that the sensitivity of self-reported data ranged from 79% to 92% for 
antihypertensive use, from 67% to 93% for statin use, and from 44% to 66% for 
antidepressant use. Specificity was high among all drug classes, ranging form 91% to 
100%. Recall for recent medication use (previous 6-month period) revealed higher 
accuracy than older periods (previous 2-year and 8-year period).  
               Third, we calculated and scaled patients’ advertisement attentiveness based on 
assumptions. We supposed that all patients had an equal chance of viewing DTC 
advertisements and that only patients with conditions that were potentially treatable by the 
promoted drugs would be interested in the DTC advertisements. However, this could be 
confounded by other factors, such as satisfaction with current treatments, accessibility to 
cable TV, content of DTC advertisements, or geographic locations.  
               Fourth, other external factors may influence the outcomes. Our study analyzed 
the influence of DTC advertising on physician visits based on the differences in personal 
characteristics, including demographics, socioeconomics, personal beliefs, health status, 
and market influence on patients. Other external factors, such as type of health insurance, 
patients’ relationship with their physicians, satisfaction with their current treatments, may 
also interact with DTC advertisements to change patients’ physician visit behaviors. Since 
we used secondary data for analyses, we lacked information on these external factors. It 
would be helpful in future research to add these external factors for analysis.  
              Fifth, our study did not examine the interaction effects between independent 
variables. For instance, income may interact with age’s influence on physician visit.  In the 
high-income population, old patients maybe more likely to visit physician than the younger 
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patients, while in the low-income population, the old patients maybe less likely to visit 
physician than the younger ones. Similar situation may also exist among other  
demographic or socioeconomic factors. Hence, future research should also consider the 
interaction effects for study. 
              Sixth, although we have described how patients’ attitudes and personal beliefs can 
be measured using Internet interactive technologies, it is more difficult to use these 
practices to target patients using the more traditional media such as  TV or radio. 
Demographic information, such as age or race, would be more useful to apply to target 
consumers on TV or radio. Studies that examine the sole effects of demographic factors on 
physician visits are recommended for future research.  
 
Conclusion 
              Our nationally representative study found multiple factors that were associated 
with different types of physician visits prompted by DTC advertisements. According to 
these factors, we decided what kinds of patient would be most likely to talk to their 
physicians as a result of DTC advertisements. Patients on regular medications, those with 
anxiety, those with high advertisement attentiveness, patients who viewed media as the 
most important source prompting them to talk with their physician, and patients with 
positive attitudes toward DTC advertisements consistently showed significant relationships 
with each type of physician visit. Patients with these characteristics were more likely to 
talk to their physicians when prompted by DTC advertisements.  
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Table 1. 
 
U.S. Promotional Spend by Direct-to-Consumer Advertising, 2003 
 
 
 Promotion Spend 
(U.S. Millions $) 
1996 1997 1998 1999 2000 2001 2002 2003 
Direct-to-Consumer 
(DTC) 
791 1,069 1,317 1,848 2,467 2,679 2,638 3,235 
 
 
Note: Direct-to-Consumer (DTC) expenditures include advertising spending on television, 
magazines and newspapers, on radio and outdoors.  
 
Source: IMS Health, Integrated Promotional ServicesTM and CMR, 6/2004  
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Table 2. 
 
Year 1998-2000 Average Return-on-Investments by Brand Revenue for 
Different Promotion Tactics 
 
 Return-On-Investment (ROI) of Promotions 
(1998-2000) Revenue Level
 
 
 
 
DTC 
advertising Detailing 
Journal 
Advertising
Physician 
Meeting & 
Events 
$25 - $100MM         $0.0 $1.0 $7.2  $0.1  
$100 -$500MM $0.2 $2.1  $4.2  $3.6  
$500+MM $1.3 $11.6  $12.2  $11.7  
 
ROI: Return-on-Investment 
MM: Million 
 
Source: Return on Investment Analysis of Pharmaceutical Promotion (RAPP), 2002 
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Table 3.   
List of Variables and Measurements 
 
Dimension 
 
Variable 
 
Measurement 
Outcome (1) Visit for 
Prescription drug 
Q448* Has an ad for a prescription drug ever 
prompted you to talk to a doctor about a 
prescription drug for yourself? 
Outcome (2) Visit for 
New condition 
Q452 Has an ad for a prescription drug ever 
prompted you to talk to a doctor about a medical 
condition, illness, or other health concern of 
your own that you had not discussed with a 
doctor before? 
Outcome (3) Visit for 
Treatment change 
Q456 Has an ad for a prescription drug ever 
prompted you to talk to a doctor about a possible 
change in treatment for a medical condition or 
illness that you already had? 
 
 
Q608 Which one of the sources is most 
important in prompting you to talk to your 
doctor?  (Media or non-media)  
Subjective Norm 
 
1) Source importance  
 
 
2) Source utilization  Q265 How often do you get information about 
health from (source)? (TV/radio, internet, 
newspapers or magazines, family and friends, a 
pharmacist, pamphlets in a doctor’s office or 
waiting room, a doctor) 
 
 
Q410-1 (DTC ads) made me aware of treatment 
that I did not know about 
Perceived Benefit 
 
1) Awareness of  
    treatments 
 
2) Patient-physician  
    communication 
 
Q410-5 (DTC ads) helped me to have better 
discussions about my health with a health 
professional 
 
 
Q410-3 (DTC ads) did not provide information 
on risks and benefits in a balanced manner 
Personal 
Beliefs 
 
 
 
 
 
 
 
 
 
 
 
 Perceived Barrier 
 
1) Unbalanced 
Information 
 
2) Physician’s 
Authority 
 Q410-4 (DTC ads) made me less confident in 
my doctor’s judgment 
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Perceived Severity 
Overall health 
 
Q214 Overall, how would you describe your 
health? 
Healthcare service 
utilization 
Q218 How long has it been since the last time 
your saw a doctor where you talked about a 
condition? 
Disease conditions 
 
Q255 Have you ever been told by a doctor that 
you have any of the following conditions? 
(Seven chronic conditions: diabetes, depression, 
arthritis, allergies, high cholesterol, asthma or 
other problems with lungs, and anxiety) 
Health 
Status Factors 
Medication use Q230 Do you currently take any prescription 
drug on a regular basis? 
Prescription insurance 
coverage 
Q820 Does your insurance or health plan pay for 
all, some, or none of the costs of Rx drugs you 
get at the pharmacy or through the mail?  
Education  
 
Q110 What is the highest level of education you 
have completed or the highest degree you have 
received? 
Socioeconomic 
Factors 
Income  
 
Q142 Which of the following income categories 
best describes your total 2000 household income 
before taxes? 
Advertisement 
attentiveness 
The proxy value of “advertisement 
attentiveness” for each respondent was based on 
the DTC spending on the drugs used to treat the 
respondent’ chronic conditions 
Market Factors 
Advertisement 
information utilization 
Q265c How often do you get information about 
health care from ads on TV or radio, in 
newspapers or magazines? 
Gender Q210 Respondent sex 
Race Q122 Do you consider yourself (race)? 
Age Q104 What is your year of birth? 
Demographic 
Factors 
 
Marital status 
 
Q109 Which of these best describes your  
           marital status? 
 
Note:          * Q # represents questions number in the questionnaire. 
                   ** See table 4. 
  
86
Table 4. 
              DTC Advertisement Spending by Therapeutic Class in 2000 
 
Diseases DTC spending ($Million) 
Diabetes 76.10 
Depression 115.10 
Athritis 265.00 
Allergies 252.00 
Athma/lung problem 279.40 
Anxiety 77.30 
High Cholesterol 211.20 
 
 
Source: National Institute of Healthcare Management (NIHCM) Foundation, Prescription  
             Drugs and Mass Media Advertising: 1999 - 2000, Med Ad News and Scott- 
             Levin Year 2000 Prescription Audit Data 
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Table 5. (1)  
Descriptive Analyses: Demographic and Socioeconomic Factors 
 
Respondent characteristics N % 
Demographic factors   
Gender   
Female  1560 48.0 
Male 1440 52.0 
 
Race   
White 2363 80.0 
Black 295 10.0 
Other race 295 10.0 
 
Age   
18-34 834 27.8 
35-64 1591 53.0 
65+ 575 19.2 
 
Marital Status   
Non-single (e.g. married, living with a partner) 1726 57.9 
Single (e.g. divorced, separated, window) 1257 42.1 
   
Socioeconomic Factors   
Education   
Less than high school graduate 259 8.7 
High school graduate or equivalent (e.g., GED) 883 29.6 
Completed some college, but no degree 683 22.9 
College graduate (e.g., B.A., A.B., B.S.) 777 26.0 
Graduate school level 384 12.9 
 
Income   
Poor (Less than $15,000) 319 11.9 
Lower income ($15,000 to $29,999) 355 13.2 
Middle income ($30,000 to $74,999) 1409 52.4 
High income ($75,000 or more) 606 22.5 
 
Prescription Drug Coverage by Insurance   
All 408 14.0 
Some 1929 66.0 
None 587 20.0 
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Table 5. (2)         
Descriptive Analyses: Health Status Factors 
 
Respondent characteristics N % 
 
Use of healthcare services   
How long has it been since you last saw a doctor where 
you talked about health condition or concern of your own? 
 
Within the last three months 1610 54.0 
More than three months, but less than one year ago 754 25.2 
More than one year ago 620 20.8 
 
Whether on any medication   
Do you currently take any prescription drug on a regular  
basis? 
Yes 1588 53.1 
No 1404 46.9 
 
Different disease conditions   
Been told have condition:    
Diabetes   
Yes 228 7.6 
No 2764 92.4 
Depression   
Yes 378 12.6 
No 2614 87.4 
Arthritis   
Yes 631 21.1 
No 2356 78.9 
Allergies   
Yes 822 27.5 
No 2163 72.5 
High cholesterol   
Yes 634 21.3 
No 2341 78.7 
Asthma or other problems with your lungs   
Yes 361 12.1 
No 2632 87.9 
Anxiety   
Yes 327 10.9 
No 2662 89.1 
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Table 5. (3) 
Descriptive Analyses: Market Factors 
 
 
Respondent characteristics N % 
 
Advertisements Information Utilization 
  
Get health care information from: Advertisements on  
TV or radio, in newspapers or magazines 
 
Often 781 26.1 
Sometimes 902 30.2 
Hardly Ever 679 22.7 
Never 626 21.0 
   
Advertisement attentiveness 
  
Very high 726 24.7 
High 820 27.9 
Low 170 5.7 
Very low 1227 41.7 
 
 
 
 
 
 
 
 
 
  
90
Table 5. (4) 
Descriptive Analyses: Personal Beliefs 
 
Respondent characteristics N % 
 
Subjective Norm   
1) Referent Source:   
Which one of the sources is most important in prompting  
you to talk to your doctor? 
Non-media source (i.e. doctors, pharmacists, friends) 2653 90.5 
Media source (i.e. TV, radio, paper, Internet) 279 9.5 
 
2) Source utilization   
How often do you get information about health from…? 
Television or radio, not including ads  
Often 452 15.2 
Sometimes 933 31.3 
Hardly Ever 800 26.8 
Never 795 26.7 
Internet websites   
Often 254 8.5 
Sometimes 521 17.4 
Hardly Ever 527 17.6 
Never 1692 56.5 
Newspapers or magazines, not including ads  
Often 540 18.1 
Sometimes 955 32.1 
Hardly Ever 733 24.6 
Never 751 25.2 
Family and friends   
Often 603 20.2 
Sometimes 1108 37.2 
Hardly Ever 733 24.6 
Never 536 18.0 
A doctor   
Often 884 30.0 
Sometimes 1122 38.1 
Hardly Ever 623 21.2 
Never 313 10.6 
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Table 5. (5) 
Descriptive Analyses: Personal Beliefs (continued) 
 
Respondent characteristics N % 
 
2) Source utilization (continued) 
How often do you get information about health from…? 
 
Pamphlets in a doctor’s office or waiting room    
Often 379 12.7 
Sometimes 1047 35.2 
Hardly Ever 843 28.3 
Never 709 23.8 
A pharmacist   
Often 335 11.3 
Sometimes 734 24.7 
Hardly Ever 856 28.9 
Never 1042 35.1 
 
Perceived Benefit 
  
1) Awareness of treatments: DTC advertisements made 
me aware of treatment that I did not know about 
   
Strongly Agree 673 22.9 
Somewhat Agree 1100 37.5 
Somewhat Disagree 383 13.1 
Strongly Disagree 777 26.5 
 
2) Patient-physician relationship: DTC advertisements 
helped me to have better discussion s about my health 
with a health professional 
   
Strongly Agree 632 21.6 
Somewhat Agree 946 32.4 
Somewhat Disagree 434 14.9 
Strongly Disagree 909 31.1 
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Table 5. (6) 
Descriptive Analyses: Personal Beliefs (continued) 
 
 
Respondent characteristics N % 
 
                              Perceived Barrier 
 
1) Unbalanced Information: DTC advertisements did not 
provide information on risks and benefits in a balanced  
manner 
 
Strongly Agree 520 18.0 
Somewhat Agree 780 27.1 
Somewhat Disagree 677 23.5 
Strongly Disagree 906 31.4 
   
2) Physician’s Authority: DTC advertisements made me 
less confident in my doctor’s judgment 
 
Strongly Agree 139 4.8 
Somewhat Agree 317 11.0 
Somewhat Disagree 608 21.1 
Strongly Disagree 1823 63.1 
 
Perceived Severity 
 
Overall Health   
Overall, how would you describe your health excellent, 
very good, good, fair or poor? 
 
Excellent 662 22.2 
Very good 959 32.1 
Good 888 29.7 
Fair 354 11.9 
Poor 124 4.2 
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Table 6.  
Summary of Dependent Variables and Intervention 
 
Variable of Interest N % 
Outcome (1): Has an ad for a prescription drug ever prompted 
you to talk to a doctor about a prescription drug for yourself? *   
Yes 801 26.9 
No 2177 73.1 
   
Outcome (2): Has an ad for a prescription drug ever prompted 
you to talk to a doctor about a medical condition, illness, or other 
health concern of your own that you had not discussed with a 
doctor before? * 486 16.3 
Yes 2489 83.7 
No   
   
Outcome (3): Has an ad for a prescription drug ever prompted 
you to talk to a doctor about a possible change in treatment for a 
medical condition or illness that you already had? *   
Yes 518 17.4 
No 2455 82.6 
 
Intervention: Have you ever seen or heard an advertisement for 
 a prescription drugs in the past 12 months?  
Yes 2563 85.8 
No  424 14.2 
 
 
* Only those who have ever seen or heard an advertisement for a prescription drugs in the 
past 12 months were asked about their physician visit.  Those who had not seen or heard an 
advertisement were coded as ‘no’. 
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Table 7. 
Multicollinearity Tests 
  
Collinearity Statistics*  
Independent Variables Tolerance VIF 
Race .913 1.095 
Age .673 1.485 
Education .707 1.414 
Income .644 1.552 
Marital status .848 1.179 
Prescription drugs coverage? .943 1.061 
Healthcare service utilization .769 1.300 
Medication usage .623 1.605 
Diabetes .868 1.152 
Depression .673 1.486 
Arthritis .505 1.979 
Allergies .385 2.600 
High cholesterol .491 2.039 
Asthma or other problems with your lungs .691 1.447 
Anxiety .703 1.423 
Advertisement information utilization .701 1.427 
Advertisement attentiveness .159 6.279 
Perceive benefit: aware of treatments  .602 1.662 
Perceive benefit: better discussions with professional .586 1.707 
Information source importance .882 1.134 
Source utilization: TV or radio, not including ads .721 1.387 
Source utilization: Internet websites .819 1.221 
Source utilization: Newspapers or magazines, not including ads .736 1.358 
Source utilization: Family and friends .848 1.179 
Source utilization: A pharmacist .802 1.247 
Source utilization: Pamphlets in a doctor's office/ waiting room .767 1.304 
Source utilization: A doctor .730 1.371 
Perceived barrier: unbalanced information .872 1.147 
Perceived barrier: less confident in my doctor's judgment .853 1.173 
Perceived severity: overall health .752 1.331 
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Table 8. 
Bivariate Analyses: Pearson Chi-square Tests 
 
Independent variables Visit for 
prescription drug
Visit for  
new condition 
Visit for 
treatment change
Demographics factors    
Sex *** ** *** 
Race * ns ** 
Age ** * *** 
Marital status ns ns ns 
Socioeconomic factors    
Education  *** 
 
** 
 
* 
Income * ns ns 
Prescription drug coverage ** ns * 
Health status factor    
Health service utilization *** *** *** 
Regularly take medication  *** *** *** 
Disease condition: Diabetes ** ns *** 
Disease condition: Depression *** *** *** 
Disease condition: Arthritis *** *** *** 
Disease condition: Allergies *** *** *** 
Disease condition: High 
cholesterol *** *** *** 
Disease condition: Asthma  *** ** *** 
Disease condition: Anxiety *** *** *** 
 
Note: Significance level       *** < 0.0001        **  < 0.05        *  < 0.25         
          “ns” means no relationship between the independent variable and the dependent  
          variable.                        
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Independent variables 
(Continued) 
Visit for 
prescription drug
Visit for  
new condition 
Visit for 
treatment change
 
Market factors 
Advertisement information utilization *** *** *** 
    
Advertisement attentiveness *** *** *** 
Personal beliefs    
 
Referent source *** *** *** 
    
Source utilization: Television or radio *** *** *** 
    
Source utilization: Internet websites *** *** *** 
    
Source utilization: Magazines or 
newspaper *** *** *** 
    
Source utilization: Family and friends *** *** *** 
    
Source utilization: A pharmacist *** *** *** 
    
Source utilization: Pamphlets *** *** *** 
    
Source utilization: A doctor *** *** *** 
    
Awareness of treatments *** *** *** 
    
Patient-physician communication *** *** *** 
    
Unbalanced information *** *** *** 
    
Physician’s authority *** *** *** 
    
Perceived severity: overall health *** *** *** 
 
Note: significance level       *** < 0.001        **  < 0.05        *  < 0.25 
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Table 9. 
 
Logistic Regression Model (1): Factors Associated with Visiting a Physician 
to Discuss a Prescription Drug Prompted by DTC Advertisements 
Variables in Model 
Odds 
Ratio 95% CI Sig. 
  Lower Upper  
Health Status Factors     
1) Whether taking any medication on regular basis? 
 
1.61 
 
1.25 
 
2.08 0.000 
 
2) Disease conditions:     
Depression 1.64 1.10 2.44 0.016 
Anxiety 1.57 1.05 2.33 0.028 
     
Market Factors 
    
Advertisement attentiveness:    0.000 
Very high  1.69 1.20 2.37 0.003 
High  1.68 1.26 2.25 0.000 
Low  .086 0.50 1.49 0.598 
Very low (reference group) 1.00    
     
Personal Beliefs 
    
-- Subjective Norm:     
1) Source utilization: get health information from a 
doctor    0.009 
Often 1.99 1.19 3.32 0.009 
Sometimes 1.58 0.96 2.59 0.71 
Hardly Ever 1.20 0.71 2.05 0.50 
Never (reference group) 1.00    
     
2) Source utilization: get health information from a 
pharmacist    0.024 
Often 1.63 1.11 2.41 0.014 
Sometimes 1.57 1.14 2.15 0.006 
Hardly Ever 1.29 0.94 1.76 0.111 
Never (reference group) 1.00    
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3) Referent Source: media as most important source 
prompting a patient to talk with doctor 10.87 7.35 16.08 0.000 
     
-- Perceived Benefit:     
1) Awareness of treatments: Rx ads made me aware 
of treatment that I did not know     0.000 
Strongly agree 3.05 1.95 4.76 0.000 
Somewhat Agree 2.33 1.52 3.56 0.000 
Somewhat Disagree 1.52 0.92 2.50 0.101 
Strongly disagree (reference group) 1.00    
     
2) Patient-doctor relationship: Rx ads made me have 
better discussion with professionals    .000 
Strongly agree 7.47 4.77 11.71 .000 
Somewhat Agree 5.46 3.54 8.41 .000 
Somewhat Disagree 2.24 1.37 3.66 0.001 
Strongly disagree (reference group) 1.00    
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Table 10. 
 
Logistic Regression Model (2): Factors Associated with Visiting a Physician 
to Discuss a New Health Condition Prompted by DTC Advertisements 
Variables in Model 
Odds 
Ratio 95% CI Sig. 
  Lower Upper  
Health Status Factors     
Disease conditions:     
Arthritis 1.80 1.35 2.41 0.000
Anxiety 1.95 1.38 2.76 0.000
     
Personal Beliefs     
-- Subjective Norm:     
1) Source utilization: get health information from 
family and friends    0.02 
Often 1.54 0.99 2.41 0.055
Sometimes 1.08 0.70 1.65 0.734
Hardly Ever 0.91 0.58 1.44 0.697
Never (reference group) 1.00    
     
2) Source utilization: get health information from a 
pamphlet in a doctor's office or waiting room    0.000
Often 2.66 1.70 4.16 0.000
Sometimes 1.29 0.86 1.95 0.219
Hardly Ever 1.25 0.81 1.91 0.316
Never (reference group) 1.00    
     
3) Referent Source: media as most important source 
prompting a patient to talk with doctor 4.78 3.53 6.49 .000 
     
-- Perceived Benefit:     
1) Awareness of treatments: Rx ads made me aware of 
treatment that I did not know     0.000
Strongly agree 3.28 1.88 5.70 0.000
Somewhat Agree 2.57 1.49 4.42 0.001
Somewhat Disagree 1.54 0.82 2.91 0.184
Strongly disagree (reference group) 1.00    
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2) Patient-doctor relationship: Rx ads made me have 
better discussion with professionals 
 
  
 
 
 
0.000
Strongly agree 5.13 3.00 8.79 0.000
Somewhat Agree 4.17 2.46 7.06 0.000
Somewhat Disagree 2.29 1.26 4.18 0.007
Strongly disagree (reference group) 1.00    
     
-- Perceived Barrier:     
Unbalanced information: Rx ads did not provide 
information on risks and benefits in a balanced manner    0.037
Strongly agree 0.81 0.54 1.22 0.312
Somewhat Agree 0.97 0.68 1.38 0.866
Somewhat Disagree 1.36 0.96 1.93 0.089
Strongly disagree (reference group) 1.00    
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Table 11. 
 
Logistic Regression Model (3): Factors Associated with Visiting a Physician 
to Discuss a Change to New Treatment Prompted by DTC Advertisements 
Variables in Model 
Odds 
Ratio 95% CI Sig. 
  Lower Upper  
Health Status Factors     
Whether taking any medication on regular basis? 2.11 1.58 2.83 0.000
 
Disease condition: anxiety 
 
1.73 
 
1.21 
 
2.48 
 
0.003
     
Demographic Factors     
Race    0.002
White 1.63 0.99 2.68 0.057
Black 2.79 1.53 5.10 0.001
Other races (reference group) 1.00    
     
 Market Factors     
Advertisement attentiveness:    .000 
Very high 3.49 2.42 5.04 0.000
High  2.38 1.69 3.35 0.000
Low  2.63 1.50 4.61 0.001
Very low (reference group) 1.00    
     
Personal Beliefs     
-- Subjective Norm:     
1) Source utilization: get health information from 
Internet websites    0.037
Often 1.71 1.15 2.54 0.008
Sometimes 1.15 0.82 1.61 0.422
Hardly Ever 0.94 0.66 1.34 0.724
Never (reference group) 1.00    
     
2) Source utilization: get health information from a 
pharmacist    0.010
Often 1.82 1.21 2.73 0.004
Sometimes 1.42 1.01 2.01 0.044
Hardly Ever 1.06 0.75 1.51 0.737
Never (reference group) 1.00    
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3) Referent Source: media as most important incentive 
source to talk with doctors 4.87 3.53 6.72 0.000
-- Perceived Benefit:     
1) Awareness of treatments: Rx ads made me aware of 
treatment that I did not know     0.001
Strongly agree 2.43 1.47 4.02 0.001
Somewhat Agree 1.72 1.06 2.80 0.029
Somewhat Disagree 1.30 0.74 2.29 0.366
Strongly disagree (reference group) 1.00    
     
2) Patient-doctor relationship: Rx ads made me have 
better discussion with professionals    0.000
Strongly agree 6.66 3.89 11.41 0.000
Somewhat Agree 5.01 2.96 8.49 0.000
Somewhat Disagree 2.97 1.65 5.33 0.000
Strongly disagree (reference group) 1.00    
     
-- Perceived Barrier:     
Unbalanced information: Rx ads made me less 
confident in my doctor’s judgment    0.034
Strongly agree 1.08 0.63 1.84 0.784
Somewhat Agree 1.66 1.15 2.39 0.007
Somewhat Disagree 1.35 0.99 1.82 0.056
Strongly disagree (reference group) 1.00    
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Figure 1.  
 
Trends in Spending on Direct-to-Consumer Advertising 
 
Source: Rosenthal et al., N Engl J Med  Feb. 14, 2002, 346 (7): 498-505, S 
 
 
 
 
 
 
 
 
 
Source: Rosenthal et al., N Engl J Med  Feb. 14, 2002, 346 (7): 498-505 
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Figure 2. 
Conceptual Framework 
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SPSS Syntax for model (1): 
 
LOGISTIC REGRESSION VAR=q448b 
  /METHOD=FSTEP(COND) q210 q122 age q110 q142 q820b q218 q230 q255a1 q255a2 q255a3  
q255a7 q255a8 q255a9 q255a11 q265a3 adattent q411b1 q411b5 q608medi 
  q265a1 q265a2 q265a4 q265a5 q265a6 q265a7 q265a8 q411b2 q411b4 q214   
 /CONTRAST (q122)=Indicator   /CONTRAST (age)=Indicator(1)  /CONTRAST (q110)=Indicator   
/CONTRAST  (q142)=Indicator(1)  /CONTRAST (q820b)=Indicator  /CONTRAST (q218)=Indicator  
/CONTRAST (adattent)=Indicator(1)  /CONTRAST (q411b1)=Indicator  /CONTRAST   
(q411b5)=Indicator  /CONTRAST (q265a1)=Indicator  /CONTRAST (q265a2)=Indicator  
/CONTRAST 
  (q265a4)=Indicator  /CONTRAST (q265a5)=Indicator  /CONTRAST 
  (q265a6)=Indicator  /CONTRAST (q265a7)=Indicator  /CONTRAST 
  (q265a8)=Indicator  /CONTRAST (q411b2)=Indicator  /CONTRAST 
  (q411b4)=Indicator  /CONTRAST (q214)=Indicator 
    /CLASSPLOT 
  /PRINT=GOODFIT SUMMARY CI(95) 
  /CRITERIA PIN(.05) POUT(.10) ITERATE(20) CUT(.5) . 
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SPSS Syntax for model (2): 
 
LOGISTIC REGRESSION VAR=q452b 
  /METHOD=FSTEP(COND) q210 age q110 q218 q230 q255a1 q255a2 q255a3 
  q255a7 q255a8 q255a9 q255a11 q265a3 adattent q411b1 q411b5 q608medi 
  q265a1 q265a2 q265a4 q265a5 q265a6 q265a7 q265a8 q411b2 q411b4 q214   
 /CONTRAST (age)=Indicator(1)  /CONTRAST (q110)=Indicator   
/CONTRAST (q218)=Indicator /CONTRAST (adattent)=Indicator(1)  /CONTRAST 
(q411b1)=Indicator  /CONTRAST 
  (q411b5)=Indicator  /CONTRAST (q265a1)=Indicator  /CONTRAST (q265a2)=Indicator  
/CONTRAST 
  (q265a4)=Indicator  /CONTRAST (q265a5)=Indicator  /CONTRAST 
  (q265a6)=Indicator  /CONTRAST (q265a7)=Indicator  /CONTRAST 
  (q265a8)=Indicator  /CONTRAST (q411b2)=Indicator  /CONTRAST 
  (q411b4)=Indicator  /CONTRAST (q214)=Indicator 
    /CLASSPLOT 
  /PRINT=GOODFIT SUMMARY CI(95) 
  /CRITERIA PIN(.05) POUT(.10) ITERATE(20) CUT(.5) . 
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SPSS Syntax for model (3): 
 
LOGISTIC REGRESSION VAR=q456b 
  /METHOD=FSTEP(COND) q210 q122 age q110 q820b q218 q230 q255a1 q255a2 q255a3  
q255a7 q255a8 q255a9 q255a11 q265a3 adattent q411b1 q411b5 q608medi 
  q265a1 q265a2 q265a4 q265a5 q265a6 q265a7 q265a8 q411b2 q411b4 q214   
 /CONTRAST (q122)=Indicator   /CONTRAST (age)=Indicator(1)  /CONTRAST (q110)=Indicator   
/CONTRAST (q820b)=Indicator  /CONTRAST (q218)=Indicator  /CONTRAST 
(adattent)=Indicator(1)  /CONTRAST (q411b1)=Indicator  /CONTRAST   (q411b5)=Indicator  
/CONTRAST (q265a1)=Indicator  /CONTRAST (q265a2)=Indicator  /CONTRAST 
  (q265a4)=Indicator  /CONTRAST (q265a5)=Indicator  /CONTRAST 
  (q265a6)=Indicator  /CONTRAST (q265a7)=Indicator  /CONTRAST 
  (q265a8)=Indicator  /CONTRAST (q411b2)=Indicator  /CONTRAST 
  (q411b4)=Indicator  /CONTRAST (q214)=Indicator 
    /CLASSPLOT 
  /PRINT=GOODFIT SUMMARY CI(95) 
  /CRITERIA PIN(.05) POUT(.10) ITERATE(20) CUT(.5) . 
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